Loading…
Reported covered position: Intern, Rep. Richard Nugent, October 2011-March 2012
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Federal Trade Commission related issues Issues related to the Patent Act, no specific bill Issues related to March-In/Bayh Dole, WTO/TRIPS Issues related to patent thickets Issues related to obviousness/ double patenting Issues related to FDA/PTO coordination Issues related to skinny labeling S.1041 A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes S.1040 -A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes S 708/ HR 1574 -- Realizing Engineering, Science and Technology Opportunities by Restoring Exclusive Patent Rights Act of 2025 (RESTORE) S.1553/HR3160-- Promoting and Respecting Economically Viable American Innovation Act (PREVAIL) S. 1546/ HR 3152-- Patent Eligibility Restoration Act of 2025 (PERA) S 2276 / HR 3269 Eliminating Thickets to Increase Competition Act (ETHIC Act) S. 43/HR 6485 Skinny Labels Big Savings Act S.2658 Medication Affordability and Patent Integrity Act S. 3452/HR 6624 Biological Intellectual Property Protection Act of 2025
RESTORE Patent Rights Act of 2025
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
AMGEN INC via AMGEN, INC.
2026 · third_quarter · Q3
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to FDA Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Issues related to biosimilars reimbursement Issues related to Supply Chain Issues related to 340B Issues related to pharmacy benefit managers Issues related to biosimilars regulatory standards Issues related to bone disease awareness and treatment Issues related to Public law 117-1769 Inflation Reduction Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S 1954 Biosimilar Red Tape Elimination Act H.R.5526 Biosimilar Red Tape Elimination Act S.3345 PBM Price Transparency and Accountability Act H.R. 6166 Lowering Drug Costs for American Families Act S.3019 No Big Blockbuster Bailouts Act HR 4317 PBM Reform Act S 3510 Biosimilar Inspection Modernization Act PL 119-75 Consolidated Appropriations Act of 2026 HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 S 3788 Clear Labels Act HR 5256 340B Access Act HR 7391 Community Health Center Drug Pricing Protection Act HR 8143/S 4323 Ensuring Access to Lower-Cost Medicines for Seniors Act S.2, Secure America Act (Reconciliation 2.0) S 3014 Ensuring Timely Access to Generics Act of 2025 S 2355 Patients Deserve Price Tags Act HR 8646 Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 HR 8800 National Defense Authorization Act for Fiscal year 2027 HR 9102 BINSA Bill COINS Act, enacted within P.L. 119-60 National Defense Authorization Act for Fiscal Year 2026 S 1414 Expedited Access to Biosimilars Act HR 10628/ S 5571 Biosimilars Access and Affordability Act S 5244 Sustain 340B Act HR 9599 Secure 340B Act HR 5509/ S 2903 Safe Step Act
Source: Senate LDA
Client: AMGEN INC · Firm: AMGEN, INC.
Federal Trade Commission related issues Issues related to the Patent Act, no specific bill Issues related to March-In/Bayh Dole, WTO/TRIPS Issues related to patent thickets Issues related to obviousness/ double patenting Issues related to FDA/PTO coordination Issues related to skinny labeling S.1041 A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes S.1040 -A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes S 708/ HR 1574 -- Realizing Engineering, Science and Technology Opportunities by Restoring Exclusive Patent Rights Act of 2025 (RESTORE) S.1553/HR3160-- Promoting and Respecting Economically Viable American Innovation Act (PREVAIL) S. 1546/ HR 3152-- Patent Eligibility Restoration Act of 2025 (PERA) S 2276 / HR 3269 Eliminating Thickets to Increase Competition Act (ETHIC Act) S. 43/HR 6485 Skinny Labels Big Savings Act S.2658 Medication Affordability and Patent Integrity Act S. 3452/HR 6624 Biological Intellectual Property Protection Act of 2025
Federal Trade Commission related issues Issues related to the Patent Act, no specific bill Issues related to March-In/Bayh Dole, WTO/TRIPS Issues related to patent thickets Issues related to obviousness/ double patenting Issues related to FDA/PTO coordination Issues related to skinny labeling S.1041 A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes S.1040 -A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes S 708/ HR 1574 -- Realizing Engineering, Science and Technology Opportunities by Restoring Exclusive Patent Rights Act of 2025 (RESTORE) S.1553/HR3160-- Promoting and Respecting Economically Viable American Innovation Act (PREVAIL) S. 1546/ HR 3152-- Patent Eligibility Restoration Act of 2025 (PERA) S 2276 / HR 3269 Eliminating Thickets to Increase Competition Act (ETHIC Act) S. 43/HR 6485 Skinny Labels Big Savings Act S.2658 Medication Affordability and Patent Integrity Act S. 3452/HR 6624 Biological Intellectual Property Protection Act of 2025
Federal Trade Commission related issues Issues related to the Patent Act, no specific bill Issues related to March-In/Bayh Dole, WTO/TRIPS Issues related to patent thickets Issues related to obviousness/ double patenting Issues related to FDA/PTO coordination Issues related to skinny labeling S.1041 A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes S.1040 -A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes S 708/ HR 1574 -- Realizing Engineering, Science and Technology Opportunities by Restoring Exclusive Patent Rights Act of 2025 (RESTORE) S.1553/HR3160-- Promoting and Respecting Economically Viable American Innovation Act (PREVAIL) S. 1546/ HR 3152-- Patent Eligibility Restoration Act of 2025 (PERA) S 2276 / HR 3269 Eliminating Thickets to Increase Competition Act (ETHIC Act) S. 43/HR 6485 Skinny Labels Big Savings Act S.2658 Medication Affordability and Patent Integrity Act S. 3452/HR 6624 Biological Intellectual Property Protection Act of 2025
Federal Trade Commission related issues Issues related to the Patent Act, no specific bill Issues related to March-In/Bayh Dole, WTO/TRIPS Issues related to patent thickets Issues related to obviousness/ double patenting Issues related to FDA/PTO coordination Issues related to skinny labeling S.1041 A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes S.1040 -A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes S 708/ HR 1574 -- Realizing Engineering, Science and Technology Opportunities by Restoring Exclusive Patent Rights Act of 2025 (RESTORE) S.1553/HR3160-- Promoting and Respecting Economically Viable American Innovation Act (PREVAIL) S. 1546/ HR 3152-- Patent Eligibility Restoration Act of 2025 (PERA) S 2276 / HR 3269 Eliminating Thickets to Increase Competition Act (ETHIC Act) S. 43/HR 6485 Skinny Labels Big Savings Act S.2658 Medication Affordability and Patent Integrity Act S. 3452/HR 6624 Biological Intellectual Property Protection Act of 2025
Federal Trade Commission related issues Issues related to the Patent Act, no specific bill Issues related to March-In/Bayh Dole, WTO/TRIPS Issues related to patent thickets Issues related to obviousness/ double patenting Issues related to FDA/PTO coordination Issues related to skinny labeling S.1041 A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes S.1040 -A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes S 708/ HR 1574 -- Realizing Engineering, Science and Technology Opportunities by Restoring Exclusive Patent Rights Act of 2025 (RESTORE) S.1553/HR3160-- Promoting and Respecting Economically Viable American Innovation Act (PREVAIL) S. 1546/ HR 3152-- Patent Eligibility Restoration Act of 2025 (PERA) S 2276 / HR 3269 Eliminating Thickets to Increase Competition Act (ETHIC Act) S. 43/HR 6485 Skinny Labels Big Savings Act S.2658 Medication Affordability and Patent Integrity Act S. 3452/HR 6624 Biological Intellectual Property Protection Act of 2025
Federal Trade Commission related issues Issues related to the Patent Act, no specific bill Issues related to March-In/Bayh Dole, WTO/TRIPS Issues related to patent thickets Issues related to obviousness/ double patenting Issues related to FDA/PTO coordination Issues related to skinny labeling S.1041 A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes S.1040 -A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes S 708/ HR 1574 -- Realizing Engineering, Science and Technology Opportunities by Restoring Exclusive Patent Rights Act of 2025 (RESTORE) S.1553/HR3160-- Promoting and Respecting Economically Viable American Innovation Act (PREVAIL) S. 1546/ HR 3152-- Patent Eligibility Restoration Act of 2025 (PERA) S 2276 / HR 3269 Eliminating Thickets to Increase Competition Act (ETHIC Act) S. 43/HR 6485 Skinny Labels Big Savings Act S.2658 Medication Affordability and Patent Integrity Act S. 3452/HR 6624 Biological Intellectual Property Protection Act of 2025
Federal Trade Commission related issues Issues related to the Patent Act, no specific bill Issues related to March-In/Bayh Dole, WTO/TRIPS Issues related to patent thickets Issues related to obviousness/ double patenting Issues related to FDA/PTO coordination Issues related to skinny labeling S.1041 A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes S.1040 -A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes S 708/ HR 1574 -- Realizing Engineering, Science and Technology Opportunities by Restoring Exclusive Patent Rights Act of 2025 (RESTORE) S.1553/HR3160-- Promoting and Respecting Economically Viable American Innovation Act (PREVAIL) S. 1546/ HR 3152-- Patent Eligibility Restoration Act of 2025 (PERA) S 2276 / HR 3269 Eliminating Thickets to Increase Competition Act (ETHIC Act) S. 43/HR 6485 Skinny Labels Big Savings Act S.2658 Medication Affordability and Patent Integrity Act S. 3452/HR 6624 Biological Intellectual Property Protection Act of 2025
Federal Trade Commission related issues Issues related to the Patent Act, no specific bill Issues related to March-In/Bayh Dole, WTO/TRIPS Issues related to patent thickets Issues related to obviousness/ double patenting Issues related to FDA/PTO coordination Issues related to skinny labeling S.1041 A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes S.1040 -A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes S 708/ HR 1574 -- Realizing Engineering, Science and Technology Opportunities by Restoring Exclusive Patent Rights Act of 2025 (RESTORE) S.1553/HR3160-- Promoting and Respecting Economically Viable American Innovation Act (PREVAIL) S. 1546/ HR 3152-- Patent Eligibility Restoration Act of 2025 (PERA) S 2276 / HR 3269 Eliminating Thickets to Increase Competition Act (ETHIC Act) S. 43/HR 6485 Skinny Labels Big Savings Act S.2658 Medication Affordability and Patent Integrity Act S. 3452/HR 6624 Biological Intellectual Property Protection Act of 2025
Federal Trade Commission related issues Issues related to the Patent Act, no specific bill Issues related to March-In/Bayh Dole, WTO/TRIPS Issues related to patent thickets Issues related to obviousness/ double patenting Issues related to FDA/PTO coordination Issues related to skinny labeling S.1041 A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes S.1040 -A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes S 708/ HR 1574 -- Realizing Engineering, Science and Technology Opportunities by Restoring Exclusive Patent Rights Act of 2025 (RESTORE) S.1553/HR3160-- Promoting and Respecting Economically Viable American Innovation Act (PREVAIL) S. 1546/ HR 3152-- Patent Eligibility Restoration Act of 2025 (PERA) S 2276 / HR 3269 Eliminating Thickets to Increase Competition Act (ETHIC Act) S. 43/HR 6485 Skinny Labels Big Savings Act S.2658 Medication Affordability and Patent Integrity Act S. 3452/HR 6624 Biological Intellectual Property Protection Act of 2025
Biological Intellectual Property Protection Act of 2025
Client: AMGEN INC · Firm: AMGEN, INC.
Federal Trade Commission related issues Issues related to the Patent Act, no specific bill Issues related to March-In/Bayh Dole, WTO/TRIPS Issues related to patent thickets Issues related to obviousness/ double patenting Issues related to FDA/PTO coordination Issues related to skinny labeling S.1041 A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes S.1040 -A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes S 708/ HR 1574 -- Realizing Engineering, Science and Technology Opportunities by Restoring Exclusive Patent Rights Act of 2025 (RESTORE) S.1553/HR3160-- Promoting and Respecting Economically Viable American Innovation Act (PREVAIL) S. 1546/ HR 3152-- Patent Eligibility Restoration Act of 2025 (PERA) S 2276 / HR 3269 Eliminating Thickets to Increase Competition Act (ETHIC Act) S. 43/HR 6485 Skinny Labels Big Savings Act S.2658 Medication Affordability and Patent Integrity Act S. 3452/HR 6624 Biological Intellectual Property Protection Act of 2025
Biological Intellectual Property Protection Act of 2025
Client: AMGEN INC · Firm: AMGEN, INC.
Issues related to tariffs Issues related to trade agreements S. 3452/HR 6624 Biological Intellectual Property Protection Act of 2025
Biological Intellectual Property Protection Act of 2025
Client: AMGEN INC · Firm: AMGEN, INC.
Federal Trade Commission related issues Issues related to the Patent Act, no specific bill Issues related to March-In/Bayh Dole, WTO/TRIPS Issues related to patent thickets Issues related to obviousness/ double patenting Issues related to FDA/PTO coordination Issues related to skinny labeling S.1041 A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes S.1040 -A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes S 708/ HR 1574 -- Realizing Engineering, Science and Technology Opportunities by Restoring Exclusive Patent Rights Act of 2025 (RESTORE) S.1553/HR3160-- Promoting and Respecting Economically Viable American Innovation Act (PREVAIL) S. 1546/ HR 3152-- Patent Eligibility Restoration Act of 2025 (PERA) S 2276 / HR 3269 Eliminating Thickets to Increase Competition Act (ETHIC Act) S. 43/HR 6485 Skinny Labels Big Savings Act S.2658 Medication Affordability and Patent Integrity Act S. 3452/HR 6624 Biological Intellectual Property Protection Act of 2025
Biological Intellectual Property Protection Act of 2025
Client: AMGEN INC · Firm: AMGEN, INC.
Issues related to tariffs Issues related to trade agreements S. 3452/HR 6624 Biological Intellectual Property Protection Act of 2025
Biological Intellectual Property Protection Act of 2025
Client: AMGEN INC · Firm: AMGEN, INC.
Issues related to tariffs Issues related to trade agreements S. 3452/HR 6624 Biological Intellectual Property Protection Act of 2025
Federal Trade Commission related issues Issues related to the Patent Act, no specific bill Issues related to March-In/Bayh Dole, WTO/TRIPS Issues related to patent thickets Issues related to obviousness/ double patenting Issues related to FDA/PTO coordination Issues related to skinny labeling S.1041 A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes S.1040 -A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes S 708/ HR 1574 -- Realizing Engineering, Science and Technology Opportunities by Restoring Exclusive Patent Rights Act of 2025 (RESTORE) S.1553/HR3160-- Promoting and Respecting Economically Viable American Innovation Act (PREVAIL) S. 1546/ HR 3152-- Patent Eligibility Restoration Act of 2025 (PERA) S 2276 / HR 3269 Eliminating Thickets to Increase Competition Act (ETHIC Act) S. 43/HR 6485 Skinny Labels Big Savings Act S.2658 Medication Affordability and Patent Integrity Act S. 3452/HR 6624 Biological Intellectual Property Protection Act of 2025
Federal Trade Commission related issues Issues related to the Patent Act, no specific bill Issues related to March-In/Bayh Dole, WTO/TRIPS Issues related to patent thickets Issues related to obviousness/ double patenting Issues related to FDA/PTO coordination Issues related to skinny labeling S.1041 A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes S.1040 -A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes S 708/ HR 1574 -- Realizing Engineering, Science and Technology Opportunities by Restoring Exclusive Patent Rights Act of 2025 (RESTORE) S.1553/HR3160-- Promoting and Respecting Economically Viable American Innovation Act (PREVAIL) S. 1546/ HR 3152-- Patent Eligibility Restoration Act of 2025 (PERA) S 2276 / HR 3269 Eliminating Thickets to Increase Competition Act (ETHIC Act) S. 43/HR 6485 Skinny Labels Big Savings Act S.2658 Medication Affordability and Patent Integrity Act S. 3452/HR 6624 Biological Intellectual Property Protection Act of 2025
Federal Trade Commission related issues Issues related to the Patent Act, no specific bill Issues related to March-In/Bayh Dole, WTO/TRIPS Issues related to patent thickets Issues related to obviousness/ double patenting Issues related to FDA/PTO coordination Issues related to skinny labeling S.1041 A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes S.1040 -A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes S 708/ HR 1574 -- Realizing Engineering, Science and Technology Opportunities by Restoring Exclusive Patent Rights Act of 2025 (RESTORE) S.1553/HR3160-- Promoting and Respecting Economically Viable American Innovation Act (PREVAIL) S. 1546/ HR 3152-- Patent Eligibility Restoration Act of 2025 (PERA) S 2276 / HR 3269 Eliminating Thickets to Increase Competition Act (ETHIC Act) S. 43/HR 6485 Skinny Labels Big Savings Act S.2658 Medication Affordability and Patent Integrity Act S. 3452/HR 6624 Biological Intellectual Property Protection Act of 2025
Federal Trade Commission related issues Issues related to the Patent Act, no specific bill Issues related to March-In/Bayh Dole, WTO/TRIPS Issues related to patent thickets Issues related to obviousness/ double patenting Issues related to FDA/PTO coordination Issues related to skinny labeling S.1041 A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes S.1040 -A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes S 708/ HR 1574 -- Realizing Engineering, Science and Technology Opportunities by Restoring Exclusive Patent Rights Act of 2025 (RESTORE) S.1553/HR3160-- Promoting and Respecting Economically Viable American Innovation Act (PREVAIL) S. 1546/ HR 3152-- Patent Eligibility Restoration Act of 2025 (PERA) S 2276 / HR 3269 Eliminating Thickets to Increase Competition Act (ETHIC Act) S. 43/HR 6485 Skinny Labels Big Savings Act S.2658 Medication Affordability and Patent Integrity Act S. 3452/HR 6624 Biological Intellectual Property Protection Act of 2025
Federal Trade Commission related issues Issues related to the Patent Act, no specific bill Issues related to March-In/Bayh Dole, WTO/TRIPS Issues related to patent thickets Issues related to obviousness/ double patenting Issues related to FDA/PTO coordination Issues related to skinny labeling S.1041 A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes S.1040 -A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes S 708/ HR 1574 -- Realizing Engineering, Science and Technology Opportunities by Restoring Exclusive Patent Rights Act of 2025 (RESTORE) S.1553/HR3160-- Promoting and Respecting Economically Viable American Innovation Act (PREVAIL) S. 1546/ HR 3152-- Patent Eligibility Restoration Act of 2025 (PERA) S 2276 / HR 3269 Eliminating Thickets to Increase Competition Act (ETHIC Act) S. 43/HR 6485 Skinny Labels Big Savings Act S.2658 Medication Affordability and Patent Integrity Act S. 3452/HR 6624 Biological Intellectual Property Protection Act of 2025
Federal Trade Commission related issues Issues related to the Patent Act, no specific bill Issues related to March-In/Bayh Dole, WTO/TRIPS Issues related to patent thickets Issues related to obviousness/ double patenting Issues related to FDA/PTO coordination Issues related to skinny labeling S.1041 A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes S.1040 -A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes S 708/ HR 1574 -- Realizing Engineering, Science and Technology Opportunities by Restoring Exclusive Patent Rights Act of 2025 (RESTORE) S.1553/HR3160-- Promoting and Respecting Economically Viable American Innovation Act (PREVAIL) S. 1546/ HR 3152-- Patent Eligibility Restoration Act of 2025 (PERA) S 2276 / HR 3269 Eliminating Thickets to Increase Competition Act (ETHIC Act) S. 43/HR 6485 Skinny Labels Big Savings Act S.2658 Medication Affordability and Patent Integrity Act S. 3452/HR 6624 Biological Intellectual Property Protection Act of 2025
Federal Trade Commission related issues Issues related to the Patent Act, no specific bill Issues related to March-In/Bayh Dole, WTO/TRIPS Issues related to patent thickets Issues related to obviousness/ double patenting Issues related to FDA/PTO coordination Issues related to skinny labeling S.1041 A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes S.1040 -A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes S 708/ HR 1574 -- Realizing Engineering, Science and Technology Opportunities by Restoring Exclusive Patent Rights Act of 2025 (RESTORE) S.1553/HR3160-- Promoting and Respecting Economically Viable American Innovation Act (PREVAIL) S. 1546/ HR 3152-- Patent Eligibility Restoration Act of 2025 (PERA) S 2276 / HR 3269 Eliminating Thickets to Increase Competition Act (ETHIC Act) S. 43/HR 6485 Skinny Labels Big Savings Act S.2658 Medication Affordability and Patent Integrity Act S. 3452/HR 6624 Biological Intellectual Property Protection Act of 2025
Federal Trade Commission related issues Issues related to the Patent Act, no specific bill Issues related to March-In/Bayh Dole, WTO/TRIPS Issues related to patent thickets Issues related to obviousness/ double patenting Issues related to FDA/PTO coordination Issues related to skinny labeling S.1041 A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes S.1040 -A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes S 708/ HR 1574 -- Realizing Engineering, Science and Technology Opportunities by Restoring Exclusive Patent Rights Act of 2025 (RESTORE) S.1553/HR3160-- Promoting and Respecting Economically Viable American Innovation Act (PREVAIL) S. 1546/ HR 3152-- Patent Eligibility Restoration Act of 2025 (PERA) S 2276 / HR 3269 Eliminating Thickets to Increase Competition Act (ETHIC Act) S. 43/HR 6485 Skinny Labels Big Savings Act S.2658 Medication Affordability and Patent Integrity Act S. 3452/HR 6624 Biological Intellectual Property Protection Act of 2025
Federal Trade Commission related issues Issues related to the Patent Act, no specific bill Issues related to March-In/Bayh Dole, WTO/TRIPS Issues related to patent thickets Issues related to obviousness/ double patenting Issues related to FDA/PTO coordination Issues related to skinny labeling S.1041 A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes S.1040 -A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes S 708/ HR 1574 -- Realizing Engineering, Science and Technology Opportunities by Restoring Exclusive Patent Rights Act of 2025 (RESTORE) S.1553/HR3160-- Promoting and Respecting Economically Viable American Innovation Act (PREVAIL) S. 1546/ HR 3152-- Patent Eligibility Restoration Act of 2025 (PERA) S 2276 / HR 3269 Eliminating Thickets to Increase Competition Act (ETHIC Act) S. 43/HR 6485 Skinny Labels Big Savings Act S.2658 Medication Affordability and Patent Integrity Act S. 3452/HR 6624 Biological Intellectual Property Protection Act of 2025
Federal Trade Commission related issues Issues related to the Patent Act, no specific bill Issues related to March-In/Bayh Dole, WTO/TRIPS Issues related to patent thickets Issues related to obviousness/ double patenting Issues related to FDA/PTO coordination Issues related to skinny labeling S.1041 A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes S.1040 -A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes S 708/ HR 1574 -- Realizing Engineering, Science and Technology Opportunities by Restoring Exclusive Patent Rights Act of 2025 (RESTORE) S.1553/HR3160-- Promoting and Respecting Economically Viable American Innovation Act (PREVAIL) S. 1546/ HR 3152-- Patent Eligibility Restoration Act of 2025 (PERA) S 2276 / HR 3269 Eliminating Thickets to Increase Competition Act (ETHIC Act) S. 43/HR 6485 Skinny Labels Big Savings Act S.2658 Medication Affordability and Patent Integrity Act S. 3452/HR 6624 Biological Intellectual Property Protection Act of 2025
Federal Trade Commission related issues Issues related to the Patent Act, no specific bill Issues related to March-In/Bayh Dole, WTO/TRIPS Issues related to patent thickets Issues related to obviousness/ double patenting Issues related to FDA/PTO coordination Issues related to skinny labeling S.1041 A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes S.1040 -A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes S 708/ HR 1574 -- Realizing Engineering, Science and Technology Opportunities by Restoring Exclusive Patent Rights Act of 2025 (RESTORE) S.1553/HR3160-- Promoting and Respecting Economically Viable American Innovation Act (PREVAIL) S. 1546/ HR 3152-- Patent Eligibility Restoration Act of 2025 (PERA) S 2276 / HR 3269 Eliminating Thickets to Increase Competition Act (ETHIC Act) S. 43/HR 6485 Skinny Labels Big Savings Act S.2658 Medication Affordability and Patent Integrity Act S. 3452/HR 6624 Biological Intellectual Property Protection Act of 2025
Federal Trade Commission related issues Issues related to the Patent Act, no specific bill Issues related to March-In/Bayh Dole, WTO/TRIPS Issues related to patent thickets Issues related to obviousness/ double patenting Issues related to FDA/PTO coordination Issues related to skinny labeling S.1041 A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes S.1040 -A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes S 708/ HR 1574 -- Realizing Engineering, Science and Technology Opportunities by Restoring Exclusive Patent Rights Act of 2025 (RESTORE) S.1553/HR3160-- Promoting and Respecting Economically Viable American Innovation Act (PREVAIL) S. 1546/ HR 3152-- Patent Eligibility Restoration Act of 2025 (PERA) S 2276 / HR 3269 Eliminating Thickets to Increase Competition Act (ETHIC Act) S. 43/HR 6485 Skinny Labels Big Savings Act S.2658 Medication Affordability and Patent Integrity Act S. 3452/HR 6624 Biological Intellectual Property Protection Act of 2025
Federal Trade Commission related issues Issues related to the Patent Act, no specific bill Issues related to March-In/Bayh Dole, WTO/TRIPS Issues related to patent thickets Issues related to obviousness/ double patenting Issues related to FDA/PTO coordination Issues related to skinny labeling S.1041 A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes S.1040 -A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes S 708/ HR 1574 -- Realizing Engineering, Science and Technology Opportunities by Restoring Exclusive Patent Rights Act of 2025 (RESTORE) S.1553/HR3160-- Promoting and Respecting Economically Viable American Innovation Act (PREVAIL) S. 1546/ HR 3152-- Patent Eligibility Restoration Act of 2025 (PERA) S 2276 / HR 3269 Eliminating Thickets to Increase Competition Act (ETHIC Act) S. 43/HR 6485 Skinny Labels Big Savings Act S.2658 Medication Affordability and Patent Integrity Act S. 3452/HR 6624 Biological Intellectual Property Protection Act of 2025
Federal Trade Commission related issues Issues related to the Patent Act, no specific bill Issues related to March-In/Bayh Dole, WTO/TRIPS Issues related to patent thickets Issues related to obviousness/ double patenting Issues related to FDA/PTO coordination Issues related to skinny labeling S.1041 A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes S.1040 -A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes S 708/ HR 1574 -- Realizing Engineering, Science and Technology Opportunities by Restoring Exclusive Patent Rights Act of 2025 (RESTORE) S.1553/HR3160-- Promoting and Respecting Economically Viable American Innovation Act (PREVAIL) S. 1546/ HR 3152-- Patent Eligibility Restoration Act of 2025 (PERA) S 2276 / HR 3269 Eliminating Thickets to Increase Competition Act (ETHIC Act) S. 43/HR 6485 Skinny Labels Big Savings Act S.2658 Medication Affordability and Patent Integrity Act S. 3452/HR 6624 Biological Intellectual Property Protection Act of 2025
Issues related to tariffs Issues related to trade agreements S. 3452/HR 6624 Biological Intellectual Property Protection Act of 2025
Issues related to tariffs Issues related to trade agreements S. 3452/HR 6624 Biological Intellectual Property Protection Act of 2025
Issues related to tariffs Issues related to trade agreements S. 3452/HR 6624 Biological Intellectual Property Protection Act of 2025
Federal Trade Commission related issues Issues related to the Patent Act, no specific bill Issues related to March-In/Bayh Dole, WTO/TRIPS Issues related to patent thickets Issues related to obviousness/ double patenting Issues related to FDA/PTO coordination Issues related to skinny labeling S.1041 A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes S.1040 -A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes S 708/ HR 1574 -- Realizing Engineering, Science and Technology Opportunities by Restoring Exclusive Patent Rights Act of 2025 (RESTORE) S.1553/HR3160-- Promoting and Respecting Economically Viable American Innovation Act (PREVAIL) S. 1546/ HR 3152-- Patent Eligibility Restoration Act of 2025 (PERA) S 2276 / HR 3269 Eliminating Thickets to Increase Competition Act (ETHIC Act) S. 43/HR 6485 Skinny Labels Big Savings Act S.2658 Medication Affordability and Patent Integrity Act S. 3452/HR 6624 Biological Intellectual Property Protection Act of 2025
Federal Trade Commission related issues Issues related to the Patent Act, no specific bill Issues related to March-In/Bayh Dole, WTO/TRIPS Issues related to patent thickets Issues related to obviousness/ double patenting Issues related to FDA/PTO coordination Issues related to skinny labeling S.1041 A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes S.1040 -A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes S 708/ HR 1574 -- Realizing Engineering, Science and Technology Opportunities by Restoring Exclusive Patent Rights Act of 2025 (RESTORE) S.1553/HR3160-- Promoting and Respecting Economically Viable American Innovation Act (PREVAIL) S. 1546/ HR 3152-- Patent Eligibility Restoration Act of 2025 (PERA) S 2276 / HR 3269 Eliminating Thickets to Increase Competition Act (ETHIC Act) S. 43/HR 6485 Skinny Labels Big Savings Act S.2658 Medication Affordability and Patent Integrity Act S. 3452/HR 6624 Biological Intellectual Property Protection Act of 2025
Federal Trade Commission related issues Issues related to the Patent Act, no specific bill Issues related to March-In/Bayh Dole, WTO/TRIPS Issues related to patent thickets Issues related to obviousness/ double patenting Issues related to FDA/PTO coordination Issues related to skinny labeling S.1041 A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes S.1040 -A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes S 708/ HR 1574 -- Realizing Engineering, Science and Technology Opportunities by Restoring Exclusive Patent Rights Act of 2025 (RESTORE) S.1553/HR3160-- Promoting and Respecting Economically Viable American Innovation Act (PREVAIL) S. 1546/ HR 3152-- Patent Eligibility Restoration Act of 2025 (PERA) S 2276 / HR 3269 Eliminating Thickets to Increase Competition Act (ETHIC Act) S. 43/HR 6485 Skinny Labels Big Savings Act S.2658 Medication Affordability and Patent Integrity Act S. 3452/HR 6624 Biological Intellectual Property Protection Act of 2025
Federal Trade Commission related issues Issues related to the Patent Act, no specific bill Issues related to March-In/Bayh Dole, WTO/TRIPS Issues related to patent thickets Issues related to obviousness/ double patenting Issues related to FDA/PTO coordination Issues related to skinny labeling S.1041 A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes S.1040 -A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes S 708/ HR 1574 -- Realizing Engineering, Science and Technology Opportunities by Restoring Exclusive Patent Rights Act of 2025 (RESTORE) S.1553/HR3160-- Promoting and Respecting Economically Viable American Innovation Act (PREVAIL) S. 1546/ HR 3152-- Patent Eligibility Restoration Act of 2025 (PERA) S 2276 / HR 3269 Eliminating Thickets to Increase Competition Act (ETHIC Act) S. 43/HR 6485 Skinny Labels Big Savings Act S.2658 Medication Affordability and Patent Integrity Act S. 3452/HR 6624 Biological Intellectual Property Protection Act of 2025
Abolish the Last Great Plantation in America Resolution
Client: AMGEN INC · Firm: AMGEN, INC.
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to reimbursement for biologics/biosimilars Issues related to PBM reform Issues related to bone disease awareness and treatment HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S.3345, PBM Price Transparency and Accountability Act HR 6166, Lowering Drug Costs for American Families Act S 3019 - No Big Blockbuster Bailouts Act S 3349 PBM Disclosure Act HR 4317 PBM Reform Act Issues related to Public law 117-1769 Inflation Reduction Act HR 1492 Ensuring Pathways to Innovative Cures Act (EPIC) HR 1672 Maintaining Investments in New Innovation Act (MINI) HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 PL 119-75 Consolidated Appropriations Act of 2026
Abolish the Last Great Plantation in America Resolution
Client: AMGEN INC · Firm: AMGEN, INC.
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to FDA Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Issues related to biosimilars reimbursement Issues related to Supply Chain Issues related to 340B Issues related to pharmacy benefit managers Issues related to biosimilars regulatory standards Issues related to bone disease awareness and treatment Issues related to Public law 117-1769 Inflation Reduction Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S 1954 Biosimilar Red Tape Elimination Act S.3345 PBM Price Transparency and Accountability Act H.R. 6166 Lowering Drug Costs for American Families Act S.3019 No Big Blockbuster Bailouts Act HR 4317 PBM Reform Act S 3510 Biosimilar Inspection Modernization Act PL 119-75 Consolidated Appropriations Act of 2026 HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 S 3788 Clear Labels Act HR 5256 340B Access Act H.R.5526 Biosimilar Red Tape Elimination Act HR 7391 Community Health Center Drug Pricing Protection Act
Abolish the Last Great Plantation in America Resolution
Client: AMGEN INC · Firm: AMGEN, INC.
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to FDA Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Issues related to biosimilars reimbursement Issues related to Supply Chain Issues related to 340B Issues related to pharmacy benefit managers Issues related to biosimilars regulatory standards Issues related to bone disease awareness and treatment Issues related to Public law 117-1769 Inflation Reduction Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S 1954 Biosimilar Red Tape Elimination Act H.R.5526 Biosimilar Red Tape Elimination Act S.3345 PBM Price Transparency and Accountability Act H.R. 6166 Lowering Drug Costs for American Families Act S.3019 No Big Blockbuster Bailouts Act HR 4317 PBM Reform Act S 3510 Biosimilar Inspection Modernization Act PL 119-75 Consolidated Appropriations Act of 2026 HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 S 3788 Clear Labels Act HR 5256 340B Access Act HR 7391 Community Health Center Drug Pricing Protection Act HR 8143/S 4323 Ensuring Access to Lower-Cost Medicines for Seniors Act S.2, Secure America Act (Reconciliation 2.0) S 3014 Ensuring Timely Access to Generics Act of 2025 S 2355 Patients Deserve Price Tags Act HR 8646 Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 HR 8800 National Defense Authorization Act for Fiscal year 2027 HR 9102 BINSA Bill COINS Act, enacted within P.L. 119-60 National Defense Authorization Act for Fiscal Year 2026 S 1414 Expedited Access to Biosimilars Act
Abolish the Last Great Plantation in America Resolution
Client: AMGEN INC · Firm: AMGEN, INC.
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to FDA Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Issues related to biosimilars reimbursement Issues related to Supply Chain Issues related to 340B Issues related to pharmacy benefit managers Issues related to biosimilars regulatory standards Issues related to bone disease awareness and treatment Issues related to Public law 117-1769 Inflation Reduction Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S 1954 Biosimilar Red Tape Elimination Act H.R.5526 Biosimilar Red Tape Elimination Act S.3345 PBM Price Transparency and Accountability Act H.R. 6166 Lowering Drug Costs for American Families Act S.3019 No Big Blockbuster Bailouts Act HR 4317 PBM Reform Act S 3510 Biosimilar Inspection Modernization Act PL 119-75 Consolidated Appropriations Act of 2026 HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 S 3788 Clear Labels Act HR 5256 340B Access Act HR 7391 Community Health Center Drug Pricing Protection Act HR 8143/S 4323 Ensuring Access to Lower-Cost Medicines for Seniors Act S.2, Secure America Act (Reconciliation 2.0) S 3014 Ensuring Timely Access to Generics Act of 2025 S 2355 Patients Deserve Price Tags Act HR 8646 Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 HR 8800 National Defense Authorization Act for Fiscal year 2027 HR 9102 BINSA Bill COINS Act, enacted within P.L. 119-60 National Defense Authorization Act for Fiscal Year 2026 S 1414 Expedited Access to Biosimilars Act HR 10628/ S 5571 Biosimilars Access and Affordability Act S 5244 Sustain 340B Act HR 9599 Secure 340B Act HR 5509/ S 2903 Safe Step Act
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to FDA Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Issues related to biosimilars reimbursement Issues related to Supply Chain Issues related to 340B Issues related to pharmacy benefit managers Issues related to biosimilars regulatory standards Issues related to bone disease awareness and treatment Issues related to Public law 117-1769 Inflation Reduction Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S 1954 Biosimilar Red Tape Elimination Act S.3345 PBM Price Transparency and Accountability Act H.R. 6166 Lowering Drug Costs for American Families Act S.3019 No Big Blockbuster Bailouts Act HR 4317 PBM Reform Act S 3510 Biosimilar Inspection Modernization Act PL 119-75 Consolidated Appropriations Act of 2026 HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 S 3788 Clear Labels Act HR 5256 340B Access Act H.R.5526 Biosimilar Red Tape Elimination Act HR 7391 Community Health Center Drug Pricing Protection Act
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to FDA Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Issues related to biosimilars reimbursement Issues related to Supply Chain Issues related to 340B Issues related to pharmacy benefit managers Issues related to biosimilars regulatory standards Issues related to bone disease awareness and treatment Issues related to Public law 117-1769 Inflation Reduction Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S 1954 Biosimilar Red Tape Elimination Act H.R.5526 Biosimilar Red Tape Elimination Act S.3345 PBM Price Transparency and Accountability Act H.R. 6166 Lowering Drug Costs for American Families Act S.3019 No Big Blockbuster Bailouts Act HR 4317 PBM Reform Act S 3510 Biosimilar Inspection Modernization Act PL 119-75 Consolidated Appropriations Act of 2026 HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 S 3788 Clear Labels Act HR 5256 340B Access Act HR 7391 Community Health Center Drug Pricing Protection Act HR 8143/S 4323 Ensuring Access to Lower-Cost Medicines for Seniors Act S.2, Secure America Act (Reconciliation 2.0) S 3014 Ensuring Timely Access to Generics Act of 2025 S 2355 Patients Deserve Price Tags Act HR 8646 Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 HR 8800 National Defense Authorization Act for Fiscal year 2027 HR 9102 BINSA Bill COINS Act, enacted within P.L. 119-60 National Defense Authorization Act for Fiscal Year 2026 S 1414 Expedited Access to Biosimilars Act
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to reimbursement for biologics/biosimilars Issues related to PBM reform Issues related to bone disease awareness and treatment HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S.3345, PBM Price Transparency and Accountability Act HR 6166, Lowering Drug Costs for American Families Act S 3019 - No Big Blockbuster Bailouts Act S 3349 PBM Disclosure Act HR 4317 PBM Reform Act Issues related to Public law 117-1769 Inflation Reduction Act HR 1492 Ensuring Pathways to Innovative Cures Act (EPIC) HR 1672 Maintaining Investments in New Innovation Act (MINI) HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 PL 119-75 Consolidated Appropriations Act of 2026
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to FDA Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Issues related to biosimilars reimbursement Issues related to Supply Chain Issues related to 340B Issues related to pharmacy benefit managers Issues related to biosimilars regulatory standards Issues related to bone disease awareness and treatment Issues related to Public law 117-1769 Inflation Reduction Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S 1954 Biosimilar Red Tape Elimination Act H.R.5526 Biosimilar Red Tape Elimination Act S.3345 PBM Price Transparency and Accountability Act H.R. 6166 Lowering Drug Costs for American Families Act S.3019 No Big Blockbuster Bailouts Act HR 4317 PBM Reform Act S 3510 Biosimilar Inspection Modernization Act PL 119-75 Consolidated Appropriations Act of 2026 HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 S 3788 Clear Labels Act HR 5256 340B Access Act HR 7391 Community Health Center Drug Pricing Protection Act HR 8143/S 4323 Ensuring Access to Lower-Cost Medicines for Seniors Act S.2, Secure America Act (Reconciliation 2.0) S 3014 Ensuring Timely Access to Generics Act of 2025 S 2355 Patients Deserve Price Tags Act HR 8646 Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 HR 8800 National Defense Authorization Act for Fiscal year 2027 HR 9102 BINSA Bill COINS Act, enacted within P.L. 119-60 National Defense Authorization Act for Fiscal Year 2026 S 1414 Expedited Access to Biosimilars Act HR 10628/ S 5571 Biosimilars Access and Affordability Act S 5244 Sustain 340B Act HR 9599 Secure 340B Act HR 5509/ S 2903 Safe Step Act
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to FDA Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Issues related to biosimilars reimbursement Issues related to Supply Chain Issues related to 340B Issues related to pharmacy benefit managers Issues related to biosimilars regulatory standards Issues related to bone disease awareness and treatment Issues related to Public law 117-1769 Inflation Reduction Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S 1954 Biosimilar Red Tape Elimination Act H.R.5526 Biosimilar Red Tape Elimination Act S.3345 PBM Price Transparency and Accountability Act H.R. 6166 Lowering Drug Costs for American Families Act S.3019 No Big Blockbuster Bailouts Act HR 4317 PBM Reform Act S 3510 Biosimilar Inspection Modernization Act PL 119-75 Consolidated Appropriations Act of 2026 HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 S 3788 Clear Labels Act HR 5256 340B Access Act HR 7391 Community Health Center Drug Pricing Protection Act HR 8143/S 4323 Ensuring Access to Lower-Cost Medicines for Seniors Act S.2, Secure America Act (Reconciliation 2.0) S 3014 Ensuring Timely Access to Generics Act of 2025 S 2355 Patients Deserve Price Tags Act HR 8646 Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 HR 8800 National Defense Authorization Act for Fiscal year 2027 HR 9102 BINSA Bill COINS Act, enacted within P.L. 119-60 National Defense Authorization Act for Fiscal Year 2026 S 1414 Expedited Access to Biosimilars Act HR 10628/ S 5571 Biosimilars Access and Affordability Act S 5244 Sustain 340B Act HR 9599 Secure 340B Act HR 5509/ S 2903 Safe Step Act
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to FDA Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Issues related to biosimilars reimbursement Issues related to Supply Chain Issues related to 340B Issues related to pharmacy benefit managers Issues related to biosimilars regulatory standards Issues related to bone disease awareness and treatment Issues related to Public law 117-1769 Inflation Reduction Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S 1954 Biosimilar Red Tape Elimination Act H.R.5526 Biosimilar Red Tape Elimination Act S.3345 PBM Price Transparency and Accountability Act H.R. 6166 Lowering Drug Costs for American Families Act S.3019 No Big Blockbuster Bailouts Act HR 4317 PBM Reform Act S 3510 Biosimilar Inspection Modernization Act PL 119-75 Consolidated Appropriations Act of 2026 HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 S 3788 Clear Labels Act HR 5256 340B Access Act HR 7391 Community Health Center Drug Pricing Protection Act HR 8143/S 4323 Ensuring Access to Lower-Cost Medicines for Seniors Act S.2, Secure America Act (Reconciliation 2.0) S 3014 Ensuring Timely Access to Generics Act of 2025 S 2355 Patients Deserve Price Tags Act HR 8646 Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 HR 8800 National Defense Authorization Act for Fiscal year 2027 HR 9102 BINSA Bill COINS Act, enacted within P.L. 119-60 National Defense Authorization Act for Fiscal Year 2026 S 1414 Expedited Access to Biosimilars Act
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to FDA Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Issues related to biosimilars reimbursement Issues related to Supply Chain Issues related to 340B Issues related to pharmacy benefit managers Issues related to biosimilars regulatory standards Issues related to bone disease awareness and treatment Issues related to Public law 117-1769 Inflation Reduction Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S 1954 Biosimilar Red Tape Elimination Act S.3345 PBM Price Transparency and Accountability Act H.R. 6166 Lowering Drug Costs for American Families Act S.3019 No Big Blockbuster Bailouts Act HR 4317 PBM Reform Act S 3510 Biosimilar Inspection Modernization Act PL 119-75 Consolidated Appropriations Act of 2026 HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 S 3788 Clear Labels Act HR 5256 340B Access Act H.R.5526 Biosimilar Red Tape Elimination Act HR 7391 Community Health Center Drug Pricing Protection Act
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to reimbursement for biologics/biosimilars Issues related to PBM reform Issues related to bone disease awareness and treatment HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S.3345, PBM Price Transparency and Accountability Act HR 6166, Lowering Drug Costs for American Families Act S 3019 - No Big Blockbuster Bailouts Act S 3349 PBM Disclosure Act HR 4317 PBM Reform Act Issues related to Public law 117-1769 Inflation Reduction Act HR 1492 Ensuring Pathways to Innovative Cures Act (EPIC) HR 1672 Maintaining Investments in New Innovation Act (MINI) HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 PL 119-75 Consolidated Appropriations Act of 2026
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to reimbursement for biologics/biosimilars Issues related to PBM reform Issues related to bone disease awareness and treatment S.3345, PBM Price Transparency and Accountability Act HR 6166, Lowering Drug Costs for American Families Act S 3019 - No Big Blockbuster Bailouts Act S 3349 PBM Disclosure Act HR 4317 PBM Reform Act Issues related to Public law 117-1769 Inflation Reduction Act HR 1672 Maintaining Investments in New Innovation Act (MINI) HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 PL 119-75 Consolidated Appropriations Act of 2026 HR 8143/S 4323 Ensuring Access to Lower-Cost Medicines for Seniors Act S.2, Secure America Act
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to reimbursement for biologics/biosimilars Issues related to PBM reform Issues related to bone disease awareness and treatment HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S.3345, PBM Price Transparency and Accountability Act HR 6166, Lowering Drug Costs for American Families Act S 3019 - No Big Blockbuster Bailouts Act S 3349 PBM Disclosure Act HR 4317 PBM Reform Act Issues related to Public law 117-1769 Inflation Reduction Act HR 1492 Ensuring Pathways to Innovative Cures Act (EPIC) HR 1672 Maintaining Investments in New Innovation Act (MINI) HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 PL 119-75 Consolidated Appropriations Act of 2026
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to reimbursement for biologics/biosimilars Issues related to PBM reform Issues related to bone disease awareness and treatment S.3345, PBM Price Transparency and Accountability Act HR 6166, Lowering Drug Costs for American Families Act S 3019 - No Big Blockbuster Bailouts Act S 3349 PBM Disclosure Act HR 4317 PBM Reform Act Issues related to Public law 117-1769 Inflation Reduction Act HR 1672 Maintaining Investments in New Innovation Act (MINI) HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 PL 119-75 Consolidated Appropriations Act of 2026 HR 8143/S 4323 Ensuring Access to Lower-Cost Medicines for Seniors Act S.2, Secure America Act HR 10628/ S 5571 Biosimilars Access and Affordability Act S 5244 Sustain 340B Act HR 9599 Secure 340B Act
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to FDA Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Issues related to biosimilars reimbursement Issues related to Supply Chain Issues related to 340B Issues related to pharmacy benefit managers Issues related to biosimilars regulatory standards Issues related to bone disease awareness and treatment Issues related to Public law 117-1769 Inflation Reduction Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S 1954 Biosimilar Red Tape Elimination Act H.R.5526 Biosimilar Red Tape Elimination Act S.3345 PBM Price Transparency and Accountability Act H.R. 6166 Lowering Drug Costs for American Families Act S.3019 No Big Blockbuster Bailouts Act HR 4317 PBM Reform Act S 3510 Biosimilar Inspection Modernization Act PL 119-75 Consolidated Appropriations Act of 2026 HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 S 3788 Clear Labels Act HR 5256 340B Access Act HR 7391 Community Health Center Drug Pricing Protection Act HR 8143/S 4323 Ensuring Access to Lower-Cost Medicines for Seniors Act S.2, Secure America Act (Reconciliation 2.0) S 3014 Ensuring Timely Access to Generics Act of 2025 S 2355 Patients Deserve Price Tags Act HR 8646 Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 HR 8800 National Defense Authorization Act for Fiscal year 2027 HR 9102 BINSA Bill COINS Act, enacted within P.L. 119-60 National Defense Authorization Act for Fiscal Year 2026 S 1414 Expedited Access to Biosimilars Act
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to FDA Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Issues related to biosimilars reimbursement Issues related to Supply Chain Issues related to 340B Issues related to pharmacy benefit managers Issues related to biosimilars regulatory standards Issues related to bone disease awareness and treatment Issues related to Public law 117-1769 Inflation Reduction Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S 1954 Biosimilar Red Tape Elimination Act S.3345 PBM Price Transparency and Accountability Act H.R. 6166 Lowering Drug Costs for American Families Act S.3019 No Big Blockbuster Bailouts Act HR 4317 PBM Reform Act S 3510 Biosimilar Inspection Modernization Act PL 119-75 Consolidated Appropriations Act of 2026 HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 S 3788 Clear Labels Act HR 5256 340B Access Act H.R.5526 Biosimilar Red Tape Elimination Act HR 7391 Community Health Center Drug Pricing Protection Act
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to FDA Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Issues related to biosimilars reimbursement Issues related to Supply Chain Issues related to 340B Issues related to pharmacy benefit managers Issues related to biosimilars regulatory standards Issues related to bone disease awareness and treatment Issues related to Public law 117-1769 Inflation Reduction Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S 1954 Biosimilar Red Tape Elimination Act H.R.5526 Biosimilar Red Tape Elimination Act S.3345 PBM Price Transparency and Accountability Act H.R. 6166 Lowering Drug Costs for American Families Act S.3019 No Big Blockbuster Bailouts Act HR 4317 PBM Reform Act S 3510 Biosimilar Inspection Modernization Act PL 119-75 Consolidated Appropriations Act of 2026 HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 S 3788 Clear Labels Act HR 5256 340B Access Act HR 7391 Community Health Center Drug Pricing Protection Act HR 8143/S 4323 Ensuring Access to Lower-Cost Medicines for Seniors Act S.2, Secure America Act (Reconciliation 2.0) S 3014 Ensuring Timely Access to Generics Act of 2025 S 2355 Patients Deserve Price Tags Act HR 8646 Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 HR 8800 National Defense Authorization Act for Fiscal year 2027 HR 9102 BINSA Bill COINS Act, enacted within P.L. 119-60 National Defense Authorization Act for Fiscal Year 2026 S 1414 Expedited Access to Biosimilars Act HR 10628/ S 5571 Biosimilars Access and Affordability Act S 5244 Sustain 340B Act HR 9599 Secure 340B Act HR 5509/ S 2903 Safe Step Act
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to reimbursement for biologics/biosimilars Issues related to PBM reform Issues related to bone disease awareness and treatment HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S.3345, PBM Price Transparency and Accountability Act HR 6166, Lowering Drug Costs for American Families Act S 3019 - No Big Blockbuster Bailouts Act S 3349 PBM Disclosure Act HR 4317 PBM Reform Act Issues related to Public law 117-1769 Inflation Reduction Act HR 1492 Ensuring Pathways to Innovative Cures Act (EPIC) HR 1672 Maintaining Investments in New Innovation Act (MINI) HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 PL 119-75 Consolidated Appropriations Act of 2026
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to FDA Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Issues related to biosimilars reimbursement Issues related to Supply Chain Issues related to 340B Issues related to pharmacy benefit managers Issues related to biosimilars regulatory standards Issues related to bone disease awareness and treatment Issues related to Public law 117-1769 Inflation Reduction Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S 1954 Biosimilar Red Tape Elimination Act H.R.5526 Biosimilar Red Tape Elimination Act S.3345 PBM Price Transparency and Accountability Act H.R. 6166 Lowering Drug Costs for American Families Act S.3019 No Big Blockbuster Bailouts Act HR 4317 PBM Reform Act S 3510 Biosimilar Inspection Modernization Act PL 119-75 Consolidated Appropriations Act of 2026 HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 S 3788 Clear Labels Act HR 5256 340B Access Act HR 7391 Community Health Center Drug Pricing Protection Act HR 8143/S 4323 Ensuring Access to Lower-Cost Medicines for Seniors Act S.2, Secure America Act (Reconciliation 2.0) S 3014 Ensuring Timely Access to Generics Act of 2025 S 2355 Patients Deserve Price Tags Act HR 8646 Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 HR 8800 National Defense Authorization Act for Fiscal year 2027 HR 9102 BINSA Bill COINS Act, enacted within P.L. 119-60 National Defense Authorization Act for Fiscal Year 2026 S 1414 Expedited Access to Biosimilars Act
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to FDA Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Issues related to biosimilars reimbursement Issues related to Supply Chain Issues related to 340B Issues related to pharmacy benefit managers Issues related to biosimilars regulatory standards Issues related to bone disease awareness and treatment Issues related to Public law 117-1769 Inflation Reduction Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S 1954 Biosimilar Red Tape Elimination Act S.3345 PBM Price Transparency and Accountability Act H.R. 6166 Lowering Drug Costs for American Families Act S.3019 No Big Blockbuster Bailouts Act HR 4317 PBM Reform Act S 3510 Biosimilar Inspection Modernization Act PL 119-75 Consolidated Appropriations Act of 2026 HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 S 3788 Clear Labels Act HR 5256 340B Access Act H.R.5526 Biosimilar Red Tape Elimination Act HR 7391 Community Health Center Drug Pricing Protection Act
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to FDA Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Issues related to biosimilars reimbursement Issues related to Supply Chain Issues related to 340B Issues related to pharmacy benefit managers Issues related to biosimilars regulatory standards Issues related to bone disease awareness and treatment Issues related to Public law 117-1769 Inflation Reduction Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S 1954 Biosimilar Red Tape Elimination Act H.R.5526 Biosimilar Red Tape Elimination Act S.3345 PBM Price Transparency and Accountability Act H.R. 6166 Lowering Drug Costs for American Families Act S.3019 No Big Blockbuster Bailouts Act HR 4317 PBM Reform Act S 3510 Biosimilar Inspection Modernization Act PL 119-75 Consolidated Appropriations Act of 2026 HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 S 3788 Clear Labels Act HR 5256 340B Access Act HR 7391 Community Health Center Drug Pricing Protection Act HR 8143/S 4323 Ensuring Access to Lower-Cost Medicines for Seniors Act S.2, Secure America Act (Reconciliation 2.0) S 3014 Ensuring Timely Access to Generics Act of 2025 S 2355 Patients Deserve Price Tags Act HR 8646 Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 HR 8800 National Defense Authorization Act for Fiscal year 2027 HR 9102 BINSA Bill COINS Act, enacted within P.L. 119-60 National Defense Authorization Act for Fiscal Year 2026 S 1414 Expedited Access to Biosimilars Act HR 10628/ S 5571 Biosimilars Access and Affordability Act S 5244 Sustain 340B Act HR 9599 Secure 340B Act HR 5509/ S 2903 Safe Step Act
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to reimbursement for biologics/biosimilars Issues related to PBM reform Issues related to bone disease awareness and treatment S.3345, PBM Price Transparency and Accountability Act HR 6166, Lowering Drug Costs for American Families Act S 3019 - No Big Blockbuster Bailouts Act S 3349 PBM Disclosure Act HR 4317 PBM Reform Act Issues related to Public law 117-1769 Inflation Reduction Act HR 1672 Maintaining Investments in New Innovation Act (MINI) HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 PL 119-75 Consolidated Appropriations Act of 2026 HR 8143/S 4323 Ensuring Access to Lower-Cost Medicines for Seniors Act S.2, Secure America Act
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to reimbursement for biologics/biosimilars Issues related to PBM reform Issues related to bone disease awareness and treatment S.3345, PBM Price Transparency and Accountability Act HR 6166, Lowering Drug Costs for American Families Act S 3019 - No Big Blockbuster Bailouts Act S 3349 PBM Disclosure Act HR 4317 PBM Reform Act Issues related to Public law 117-1769 Inflation Reduction Act HR 1672 Maintaining Investments in New Innovation Act (MINI) HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 PL 119-75 Consolidated Appropriations Act of 2026 HR 8143/S 4323 Ensuring Access to Lower-Cost Medicines for Seniors Act S.2, Secure America Act HR 10628/ S 5571 Biosimilars Access and Affordability Act S 5244 Sustain 340B Act HR 9599 Secure 340B Act
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to reimbursement for biologics/biosimilars Issues related to PBM reform Issues related to bone disease awareness and treatment HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S.3345, PBM Price Transparency and Accountability Act HR 6166, Lowering Drug Costs for American Families Act S 3019 - No Big Blockbuster Bailouts Act S 3349 PBM Disclosure Act HR 4317 PBM Reform Act Issues related to Public law 117-1769 Inflation Reduction Act HR 1492 Ensuring Pathways to Innovative Cures Act (EPIC) HR 1672 Maintaining Investments in New Innovation Act (MINI) HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 PL 119-75 Consolidated Appropriations Act of 2026
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to reimbursement for biologics/biosimilars Issues related to PBM reform Issues related to bone disease awareness and treatment S.3345, PBM Price Transparency and Accountability Act HR 6166, Lowering Drug Costs for American Families Act S 3019 - No Big Blockbuster Bailouts Act S 3349 PBM Disclosure Act HR 4317 PBM Reform Act Issues related to Public law 117-1769 Inflation Reduction Act HR 1672 Maintaining Investments in New Innovation Act (MINI) HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 PL 119-75 Consolidated Appropriations Act of 2026 HR 8143/S 4323 Ensuring Access to Lower-Cost Medicines for Seniors Act S.2, Secure America Act HR 10628/ S 5571 Biosimilars Access and Affordability Act S 5244 Sustain 340B Act HR 9599 Secure 340B Act
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to FDA Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Issues related to biosimilars reimbursement Issues related to Supply Chain Issues related to 340B Issues related to pharmacy benefit managers Issues related to biosimilars regulatory standards Issues related to bone disease awareness and treatment Issues related to Public law 117-1769 Inflation Reduction Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S 1954 Biosimilar Red Tape Elimination Act H.R.5526 Biosimilar Red Tape Elimination Act S.3345 PBM Price Transparency and Accountability Act H.R. 6166 Lowering Drug Costs for American Families Act S.3019 No Big Blockbuster Bailouts Act HR 4317 PBM Reform Act S 3510 Biosimilar Inspection Modernization Act PL 119-75 Consolidated Appropriations Act of 2026 HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 S 3788 Clear Labels Act HR 5256 340B Access Act HR 7391 Community Health Center Drug Pricing Protection Act HR 8143/S 4323 Ensuring Access to Lower-Cost Medicines for Seniors Act S.2, Secure America Act (Reconciliation 2.0) S 3014 Ensuring Timely Access to Generics Act of 2025 S 2355 Patients Deserve Price Tags Act HR 8646 Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 HR 8800 National Defense Authorization Act for Fiscal year 2027 HR 9102 BINSA Bill COINS Act, enacted within P.L. 119-60 National Defense Authorization Act for Fiscal Year 2026 S 1414 Expedited Access to Biosimilars Act
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to FDA Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Issues related to biosimilars reimbursement Issues related to Supply Chain Issues related to 340B Issues related to pharmacy benefit managers Issues related to biosimilars regulatory standards Issues related to bone disease awareness and treatment Issues related to Public law 117-1769 Inflation Reduction Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S 1954 Biosimilar Red Tape Elimination Act S.3345 PBM Price Transparency and Accountability Act H.R. 6166 Lowering Drug Costs for American Families Act S.3019 No Big Blockbuster Bailouts Act HR 4317 PBM Reform Act S 3510 Biosimilar Inspection Modernization Act PL 119-75 Consolidated Appropriations Act of 2026 HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 S 3788 Clear Labels Act HR 5256 340B Access Act H.R.5526 Biosimilar Red Tape Elimination Act HR 7391 Community Health Center Drug Pricing Protection Act
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to FDA Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Issues related to biosimilars reimbursement Issues related to Supply Chain Issues related to 340B Issues related to pharmacy benefit managers Issues related to biosimilars regulatory standards Issues related to bone disease awareness and treatment Issues related to Public law 117-1769 Inflation Reduction Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S 1954 Biosimilar Red Tape Elimination Act H.R.5526 Biosimilar Red Tape Elimination Act S.3345 PBM Price Transparency and Accountability Act H.R. 6166 Lowering Drug Costs for American Families Act S.3019 No Big Blockbuster Bailouts Act HR 4317 PBM Reform Act S 3510 Biosimilar Inspection Modernization Act PL 119-75 Consolidated Appropriations Act of 2026 HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 S 3788 Clear Labels Act HR 5256 340B Access Act HR 7391 Community Health Center Drug Pricing Protection Act HR 8143/S 4323 Ensuring Access to Lower-Cost Medicines for Seniors Act S.2, Secure America Act (Reconciliation 2.0) S 3014 Ensuring Timely Access to Generics Act of 2025 S 2355 Patients Deserve Price Tags Act HR 8646 Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 HR 8800 National Defense Authorization Act for Fiscal year 2027 HR 9102 BINSA Bill COINS Act, enacted within P.L. 119-60 National Defense Authorization Act for Fiscal Year 2026 S 1414 Expedited Access to Biosimilars Act HR 10628/ S 5571 Biosimilars Access and Affordability Act S 5244 Sustain 340B Act HR 9599 Secure 340B Act HR 5509/ S 2903 Safe Step Act
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to reimbursement for biologics/biosimilars Issues related to PBM reform Issues related to bone disease awareness and treatment S.3345, PBM Price Transparency and Accountability Act HR 6166, Lowering Drug Costs for American Families Act S 3019 - No Big Blockbuster Bailouts Act S 3349 PBM Disclosure Act HR 4317 PBM Reform Act Issues related to Public law 117-1769 Inflation Reduction Act HR 1672 Maintaining Investments in New Innovation Act (MINI) HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 PL 119-75 Consolidated Appropriations Act of 2026 HR 8143/S 4323 Ensuring Access to Lower-Cost Medicines for Seniors Act S.2, Secure America Act
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to FDA Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Issues related to biosimilars reimbursement Issues related to Supply Chain Issues related to 340B Issues related to pharmacy benefit managers Issues related to biosimilars regulatory standards Issues related to bone disease awareness and treatment Issues related to Public law 117-1769 Inflation Reduction Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S 1954 Biosimilar Red Tape Elimination Act H.R.5526 Biosimilar Red Tape Elimination Act S.3345 PBM Price Transparency and Accountability Act H.R. 6166 Lowering Drug Costs for American Families Act S.3019 No Big Blockbuster Bailouts Act HR 4317 PBM Reform Act S 3510 Biosimilar Inspection Modernization Act PL 119-75 Consolidated Appropriations Act of 2026 HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 S 3788 Clear Labels Act HR 5256 340B Access Act HR 7391 Community Health Center Drug Pricing Protection Act HR 8143/S 4323 Ensuring Access to Lower-Cost Medicines for Seniors Act S.2, Secure America Act (Reconciliation 2.0) S 3014 Ensuring Timely Access to Generics Act of 2025 S 2355 Patients Deserve Price Tags Act HR 8646 Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 HR 8800 National Defense Authorization Act for Fiscal year 2027 HR 9102 BINSA Bill COINS Act, enacted within P.L. 119-60 National Defense Authorization Act for Fiscal Year 2026 S 1414 Expedited Access to Biosimilars Act HR 10628/ S 5571 Biosimilars Access and Affordability Act S 5244 Sustain 340B Act HR 9599 Secure 340B Act HR 5509/ S 2903 Safe Step Act
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to FDA Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Issues related to biosimilars reimbursement Issues related to Supply Chain Issues related to 340B Issues related to pharmacy benefit managers Issues related to biosimilars regulatory standards Issues related to bone disease awareness and treatment Issues related to Public law 117-1769 Inflation Reduction Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S 1954 Biosimilar Red Tape Elimination Act H.R.5526 Biosimilar Red Tape Elimination Act S.3345 PBM Price Transparency and Accountability Act H.R. 6166 Lowering Drug Costs for American Families Act S.3019 No Big Blockbuster Bailouts Act HR 4317 PBM Reform Act S 3510 Biosimilar Inspection Modernization Act PL 119-75 Consolidated Appropriations Act of 2026 HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 S 3788 Clear Labels Act HR 5256 340B Access Act HR 7391 Community Health Center Drug Pricing Protection Act HR 8143/S 4323 Ensuring Access to Lower-Cost Medicines for Seniors Act S.2, Secure America Act (Reconciliation 2.0) S 3014 Ensuring Timely Access to Generics Act of 2025 S 2355 Patients Deserve Price Tags Act HR 8646 Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 HR 8800 National Defense Authorization Act for Fiscal year 2027 HR 9102 BINSA Bill COINS Act, enacted within P.L. 119-60 National Defense Authorization Act for Fiscal Year 2026 S 1414 Expedited Access to Biosimilars Act
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to FDA Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Issues related to biosimilars reimbursement Issues related to Supply Chain Issues related to 340B Issues related to pharmacy benefit managers Issues related to biosimilars regulatory standards Issues related to bone disease awareness and treatment Issues related to Public law 117-1769 Inflation Reduction Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S 1954 Biosimilar Red Tape Elimination Act S.3345 PBM Price Transparency and Accountability Act H.R. 6166 Lowering Drug Costs for American Families Act S.3019 No Big Blockbuster Bailouts Act HR 4317 PBM Reform Act S 3510 Biosimilar Inspection Modernization Act PL 119-75 Consolidated Appropriations Act of 2026 HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 S 3788 Clear Labels Act HR 5256 340B Access Act H.R.5526 Biosimilar Red Tape Elimination Act HR 7391 Community Health Center Drug Pricing Protection Act
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to FDA Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Issues related to biosimilars reimbursement Issues related to Supply Chain Issues related to 340B Issues related to pharmacy benefit managers Issues related to biosimilars regulatory standards Issues related to bone disease awareness and treatment Issues related to Public law 117-1769 Inflation Reduction Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S 1954 Biosimilar Red Tape Elimination Act H.R.5526 Biosimilar Red Tape Elimination Act S.3345 PBM Price Transparency and Accountability Act H.R. 6166 Lowering Drug Costs for American Families Act S.3019 No Big Blockbuster Bailouts Act HR 4317 PBM Reform Act S 3510 Biosimilar Inspection Modernization Act PL 119-75 Consolidated Appropriations Act of 2026 HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 S 3788 Clear Labels Act HR 5256 340B Access Act HR 7391 Community Health Center Drug Pricing Protection Act HR 8143/S 4323 Ensuring Access to Lower-Cost Medicines for Seniors Act S.2, Secure America Act (Reconciliation 2.0) S 3014 Ensuring Timely Access to Generics Act of 2025 S 2355 Patients Deserve Price Tags Act HR 8646 Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 HR 8800 National Defense Authorization Act for Fiscal year 2027 HR 9102 BINSA Bill COINS Act, enacted within P.L. 119-60 National Defense Authorization Act for Fiscal Year 2026 S 1414 Expedited Access to Biosimilars Act HR 10628/ S 5571 Biosimilars Access and Affordability Act S 5244 Sustain 340B Act HR 9599 Secure 340B Act HR 5509/ S 2903 Safe Step Act
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to FDA Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Issues related to biosimilars reimbursement Issues related to Supply Chain Issues related to 340B Issues related to pharmacy benefit managers Issues related to biosimilars regulatory standards Issues related to bone disease awareness and treatment Issues related to Public law 117-1769 Inflation Reduction Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S 1954 Biosimilar Red Tape Elimination Act H.R.5526 Biosimilar Red Tape Elimination Act S.3345 PBM Price Transparency and Accountability Act H.R. 6166 Lowering Drug Costs for American Families Act S.3019 No Big Blockbuster Bailouts Act HR 4317 PBM Reform Act S 3510 Biosimilar Inspection Modernization Act PL 119-75 Consolidated Appropriations Act of 2026 HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 S 3788 Clear Labels Act HR 5256 340B Access Act HR 7391 Community Health Center Drug Pricing Protection Act HR 8143/S 4323 Ensuring Access to Lower-Cost Medicines for Seniors Act S.2, Secure America Act (Reconciliation 2.0) S 3014 Ensuring Timely Access to Generics Act of 2025 S 2355 Patients Deserve Price Tags Act HR 8646 Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 HR 8800 National Defense Authorization Act for Fiscal year 2027 HR 9102 BINSA Bill COINS Act, enacted within P.L. 119-60 National Defense Authorization Act for Fiscal Year 2026 S 1414 Expedited Access to Biosimilars Act
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to FDA Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Issues related to biosimilars reimbursement Issues related to Supply Chain Issues related to 340B Issues related to pharmacy benefit managers Issues related to biosimilars regulatory standards Issues related to bone disease awareness and treatment Issues related to Public law 117-1769 Inflation Reduction Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S 1954 Biosimilar Red Tape Elimination Act S.3345 PBM Price Transparency and Accountability Act H.R. 6166 Lowering Drug Costs for American Families Act S.3019 No Big Blockbuster Bailouts Act HR 4317 PBM Reform Act S 3510 Biosimilar Inspection Modernization Act PL 119-75 Consolidated Appropriations Act of 2026 HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 S 3788 Clear Labels Act HR 5256 340B Access Act H.R.5526 Biosimilar Red Tape Elimination Act HR 7391 Community Health Center Drug Pricing Protection Act
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to FDA Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Issues related to biosimilars reimbursement Issues related to Supply Chain Issues related to 340B Issues related to pharmacy benefit managers Issues related to biosimilars regulatory standards Issues related to bone disease awareness and treatment Issues related to Public law 117-1769 Inflation Reduction Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S 1954 Biosimilar Red Tape Elimination Act H.R.5526 Biosimilar Red Tape Elimination Act S.3345 PBM Price Transparency and Accountability Act H.R. 6166 Lowering Drug Costs for American Families Act S.3019 No Big Blockbuster Bailouts Act HR 4317 PBM Reform Act S 3510 Biosimilar Inspection Modernization Act PL 119-75 Consolidated Appropriations Act of 2026 HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 S 3788 Clear Labels Act HR 5256 340B Access Act HR 7391 Community Health Center Drug Pricing Protection Act HR 8143/S 4323 Ensuring Access to Lower-Cost Medicines for Seniors Act S.2, Secure America Act (Reconciliation 2.0) S 3014 Ensuring Timely Access to Generics Act of 2025 S 2355 Patients Deserve Price Tags Act HR 8646 Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 HR 8800 National Defense Authorization Act for Fiscal year 2027 HR 9102 BINSA Bill COINS Act, enacted within P.L. 119-60 National Defense Authorization Act for Fiscal Year 2026 S 1414 Expedited Access to Biosimilars Act HR 10628/ S 5571 Biosimilars Access and Affordability Act S 5244 Sustain 340B Act HR 9599 Secure 340B Act HR 5509/ S 2903 Safe Step Act
District of Columbia Transportation Funding Equality Act
Client: AMGEN INC · Firm: AMGEN, INC.
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to FDA Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Issues related to biosimilars reimbursement Issues related to Supply Chain Issues related to 340B Issues related to pharmacy benefit managers Issues related to biosimilars regulatory standards Issues related to bone disease awareness and treatment Issues related to Public law 117-1769 Inflation Reduction Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S 1954 Biosimilar Red Tape Elimination Act H.R.5526 Biosimilar Red Tape Elimination Act S.3345 PBM Price Transparency and Accountability Act H.R. 6166 Lowering Drug Costs for American Families Act S.3019 No Big Blockbuster Bailouts Act HR 4317 PBM Reform Act S 3510 Biosimilar Inspection Modernization Act PL 119-75 Consolidated Appropriations Act of 2026 HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 S 3788 Clear Labels Act HR 5256 340B Access Act HR 7391 Community Health Center Drug Pricing Protection Act HR 8143/S 4323 Ensuring Access to Lower-Cost Medicines for Seniors Act S.2, Secure America Act (Reconciliation 2.0) S 3014 Ensuring Timely Access to Generics Act of 2025 S 2355 Patients Deserve Price Tags Act HR 8646 Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 HR 8800 National Defense Authorization Act for Fiscal year 2027 HR 9102 BINSA Bill COINS Act, enacted within P.L. 119-60 National Defense Authorization Act for Fiscal Year 2026 S 1414 Expedited Access to Biosimilars Act HR 10628/ S 5571 Biosimilars Access and Affordability Act S 5244 Sustain 340B Act HR 9599 Secure 340B Act HR 5509/ S 2903 Safe Step Act
District of Columbia Transportation Funding Equality Act
Client: AMGEN INC · Firm: AMGEN, INC.
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to FDA Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Issues related to biosimilars reimbursement Issues related to Supply Chain Issues related to 340B Issues related to pharmacy benefit managers Issues related to biosimilars regulatory standards Issues related to bone disease awareness and treatment Issues related to Public law 117-1769 Inflation Reduction Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S 1954 Biosimilar Red Tape Elimination Act H.R.5526 Biosimilar Red Tape Elimination Act S.3345 PBM Price Transparency and Accountability Act H.R. 6166 Lowering Drug Costs for American Families Act S.3019 No Big Blockbuster Bailouts Act HR 4317 PBM Reform Act S 3510 Biosimilar Inspection Modernization Act PL 119-75 Consolidated Appropriations Act of 2026 HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 S 3788 Clear Labels Act HR 5256 340B Access Act HR 7391 Community Health Center Drug Pricing Protection Act HR 8143/S 4323 Ensuring Access to Lower-Cost Medicines for Seniors Act S.2, Secure America Act (Reconciliation 2.0) S 3014 Ensuring Timely Access to Generics Act of 2025 S 2355 Patients Deserve Price Tags Act HR 8646 Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 HR 8800 National Defense Authorization Act for Fiscal year 2027 HR 9102 BINSA Bill COINS Act, enacted within P.L. 119-60 National Defense Authorization Act for Fiscal Year 2026 S 1414 Expedited Access to Biosimilars Act
District of Columbia Transportation Funding Equality Act
Client: AMGEN INC · Firm: AMGEN, INC.
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to reimbursement for biologics/biosimilars Issues related to PBM reform Issues related to bone disease awareness and treatment S.3345, PBM Price Transparency and Accountability Act HR 6166, Lowering Drug Costs for American Families Act S 3019 - No Big Blockbuster Bailouts Act S 3349 PBM Disclosure Act HR 4317 PBM Reform Act Issues related to Public law 117-1769 Inflation Reduction Act HR 1672 Maintaining Investments in New Innovation Act (MINI) HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 PL 119-75 Consolidated Appropriations Act of 2026 HR 8143/S 4323 Ensuring Access to Lower-Cost Medicines for Seniors Act S.2, Secure America Act HR 10628/ S 5571 Biosimilars Access and Affordability Act S 5244 Sustain 340B Act HR 9599 Secure 340B Act
District of Columbia Transportation Funding Equality Act
Client: AMGEN INC · Firm: AMGEN, INC.
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to reimbursement for biologics/biosimilars Issues related to PBM reform Issues related to bone disease awareness and treatment HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S.3345, PBM Price Transparency and Accountability Act HR 6166, Lowering Drug Costs for American Families Act S 3019 - No Big Blockbuster Bailouts Act S 3349 PBM Disclosure Act HR 4317 PBM Reform Act Issues related to Public law 117-1769 Inflation Reduction Act HR 1492 Ensuring Pathways to Innovative Cures Act (EPIC) HR 1672 Maintaining Investments in New Innovation Act (MINI) HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 PL 119-75 Consolidated Appropriations Act of 2026
District of Columbia Transportation Funding Equality Act
Client: AMGEN INC · Firm: AMGEN, INC.
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to FDA Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Issues related to biosimilars reimbursement Issues related to Supply Chain Issues related to 340B Issues related to pharmacy benefit managers Issues related to biosimilars regulatory standards Issues related to bone disease awareness and treatment Issues related to Public law 117-1769 Inflation Reduction Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S 1954 Biosimilar Red Tape Elimination Act S.3345 PBM Price Transparency and Accountability Act H.R. 6166 Lowering Drug Costs for American Families Act S.3019 No Big Blockbuster Bailouts Act HR 4317 PBM Reform Act S 3510 Biosimilar Inspection Modernization Act PL 119-75 Consolidated Appropriations Act of 2026 HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 S 3788 Clear Labels Act HR 5256 340B Access Act H.R.5526 Biosimilar Red Tape Elimination Act HR 7391 Community Health Center Drug Pricing Protection Act
District of Columbia Transportation Funding Equality Act
Client: AMGEN INC · Firm: AMGEN, INC.
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to reimbursement for biologics/biosimilars Issues related to PBM reform Issues related to bone disease awareness and treatment S.3345, PBM Price Transparency and Accountability Act HR 6166, Lowering Drug Costs for American Families Act S 3019 - No Big Blockbuster Bailouts Act S 3349 PBM Disclosure Act HR 4317 PBM Reform Act Issues related to Public law 117-1769 Inflation Reduction Act HR 1672 Maintaining Investments in New Innovation Act (MINI) HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 PL 119-75 Consolidated Appropriations Act of 2026 HR 8143/S 4323 Ensuring Access to Lower-Cost Medicines for Seniors Act S.2, Secure America Act
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to FDA Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Issues related to biosimilars reimbursement Issues related to Supply Chain Issues related to 340B Issues related to pharmacy benefit managers Issues related to biosimilars regulatory standards Issues related to bone disease awareness and treatment Issues related to Public law 117-1769 Inflation Reduction Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S 1954 Biosimilar Red Tape Elimination Act H.R.5526 Biosimilar Red Tape Elimination Act S.3345 PBM Price Transparency and Accountability Act H.R. 6166 Lowering Drug Costs for American Families Act S.3019 No Big Blockbuster Bailouts Act HR 4317 PBM Reform Act S 3510 Biosimilar Inspection Modernization Act PL 119-75 Consolidated Appropriations Act of 2026 HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 S 3788 Clear Labels Act HR 5256 340B Access Act HR 7391 Community Health Center Drug Pricing Protection Act HR 8143/S 4323 Ensuring Access to Lower-Cost Medicines for Seniors Act S.2, Secure America Act (Reconciliation 2.0) S 3014 Ensuring Timely Access to Generics Act of 2025 S 2355 Patients Deserve Price Tags Act HR 8646 Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 HR 8800 National Defense Authorization Act for Fiscal year 2027 HR 9102 BINSA Bill COINS Act, enacted within P.L. 119-60 National Defense Authorization Act for Fiscal Year 2026 S 1414 Expedited Access to Biosimilars Act
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to FDA Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Issues related to biosimilars reimbursement Issues related to Supply Chain Issues related to 340B Issues related to pharmacy benefit managers Issues related to biosimilars regulatory standards Issues related to bone disease awareness and treatment Issues related to Public law 117-1769 Inflation Reduction Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S 1954 Biosimilar Red Tape Elimination Act S.3345 PBM Price Transparency and Accountability Act H.R. 6166 Lowering Drug Costs for American Families Act S.3019 No Big Blockbuster Bailouts Act HR 4317 PBM Reform Act S 3510 Biosimilar Inspection Modernization Act PL 119-75 Consolidated Appropriations Act of 2026 HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 S 3788 Clear Labels Act HR 5256 340B Access Act H.R.5526 Biosimilar Red Tape Elimination Act HR 7391 Community Health Center Drug Pricing Protection Act
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to FDA Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Issues related to biosimilars reimbursement Issues related to Supply Chain Issues related to 340B Issues related to pharmacy benefit managers Issues related to biosimilars regulatory standards Issues related to bone disease awareness and treatment Issues related to Public law 117-1769 Inflation Reduction Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S 1954 Biosimilar Red Tape Elimination Act H.R.5526 Biosimilar Red Tape Elimination Act S.3345 PBM Price Transparency and Accountability Act H.R. 6166 Lowering Drug Costs for American Families Act S.3019 No Big Blockbuster Bailouts Act HR 4317 PBM Reform Act S 3510 Biosimilar Inspection Modernization Act PL 119-75 Consolidated Appropriations Act of 2026 HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 S 3788 Clear Labels Act HR 5256 340B Access Act HR 7391 Community Health Center Drug Pricing Protection Act HR 8143/S 4323 Ensuring Access to Lower-Cost Medicines for Seniors Act S.2, Secure America Act (Reconciliation 2.0) S 3014 Ensuring Timely Access to Generics Act of 2025 S 2355 Patients Deserve Price Tags Act HR 8646 Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 HR 8800 National Defense Authorization Act for Fiscal year 2027 HR 9102 BINSA Bill COINS Act, enacted within P.L. 119-60 National Defense Authorization Act for Fiscal Year 2026 S 1414 Expedited Access to Biosimilars Act HR 10628/ S 5571 Biosimilars Access and Affordability Act S 5244 Sustain 340B Act HR 9599 Secure 340B Act HR 5509/ S 2903 Safe Step Act
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to FDA Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Issues related to biosimilars reimbursement Issues related to Supply Chain Issues related to 340B Issues related to pharmacy benefit managers Issues related to biosimilars regulatory standards Issues related to bone disease awareness and treatment Issues related to Public law 117-1769 Inflation Reduction Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S 1954 Biosimilar Red Tape Elimination Act H.R.5526 Biosimilar Red Tape Elimination Act S.3345 PBM Price Transparency and Accountability Act H.R. 6166 Lowering Drug Costs for American Families Act S.3019 No Big Blockbuster Bailouts Act HR 4317 PBM Reform Act S 3510 Biosimilar Inspection Modernization Act PL 119-75 Consolidated Appropriations Act of 2026 HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 S 3788 Clear Labels Act HR 5256 340B Access Act HR 7391 Community Health Center Drug Pricing Protection Act HR 8143/S 4323 Ensuring Access to Lower-Cost Medicines for Seniors Act S.2, Secure America Act (Reconciliation 2.0) S 3014 Ensuring Timely Access to Generics Act of 2025 S 2355 Patients Deserve Price Tags Act HR 8646 Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 HR 8800 National Defense Authorization Act for Fiscal year 2027 HR 9102 BINSA Bill COINS Act, enacted within P.L. 119-60 National Defense Authorization Act for Fiscal Year 2026 S 1414 Expedited Access to Biosimilars Act HR 10628/ S 5571 Biosimilars Access and Affordability Act S 5244 Sustain 340B Act HR 9599 Secure 340B Act HR 5509/ S 2903 Safe Step Act
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to FDA Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Issues related to biosimilars reimbursement Issues related to Supply Chain Issues related to 340B Issues related to pharmacy benefit managers Issues related to biosimilars regulatory standards Issues related to bone disease awareness and treatment Issues related to Public law 117-1769 Inflation Reduction Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S 1954 Biosimilar Red Tape Elimination Act S.3345 PBM Price Transparency and Accountability Act H.R. 6166 Lowering Drug Costs for American Families Act S.3019 No Big Blockbuster Bailouts Act HR 4317 PBM Reform Act S 3510 Biosimilar Inspection Modernization Act PL 119-75 Consolidated Appropriations Act of 2026 HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 S 3788 Clear Labels Act HR 5256 340B Access Act H.R.5526 Biosimilar Red Tape Elimination Act HR 7391 Community Health Center Drug Pricing Protection Act
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to FDA Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Issues related to biosimilars reimbursement Issues related to Supply Chain Issues related to 340B Issues related to pharmacy benefit managers Issues related to biosimilars regulatory standards Issues related to bone disease awareness and treatment Issues related to Public law 117-1769 Inflation Reduction Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S 1954 Biosimilar Red Tape Elimination Act H.R.5526 Biosimilar Red Tape Elimination Act S.3345 PBM Price Transparency and Accountability Act H.R. 6166 Lowering Drug Costs for American Families Act S.3019 No Big Blockbuster Bailouts Act HR 4317 PBM Reform Act S 3510 Biosimilar Inspection Modernization Act PL 119-75 Consolidated Appropriations Act of 2026 HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 S 3788 Clear Labels Act HR 5256 340B Access Act HR 7391 Community Health Center Drug Pricing Protection Act HR 8143/S 4323 Ensuring Access to Lower-Cost Medicines for Seniors Act S.2, Secure America Act (Reconciliation 2.0) S 3014 Ensuring Timely Access to Generics Act of 2025 S 2355 Patients Deserve Price Tags Act HR 8646 Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 HR 8800 National Defense Authorization Act for Fiscal year 2027 HR 9102 BINSA Bill COINS Act, enacted within P.L. 119-60 National Defense Authorization Act for Fiscal Year 2026 S 1414 Expedited Access to Biosimilars Act
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to reimbursement for biologics/biosimilars Issues related to PBM reform Issues related to bone disease awareness and treatment S.3345, PBM Price Transparency and Accountability Act HR 6166, Lowering Drug Costs for American Families Act S 3019 - No Big Blockbuster Bailouts Act S 3349 PBM Disclosure Act HR 4317 PBM Reform Act Issues related to Public law 117-1769 Inflation Reduction Act HR 1672 Maintaining Investments in New Innovation Act (MINI) HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 PL 119-75 Consolidated Appropriations Act of 2026 HR 8143/S 4323 Ensuring Access to Lower-Cost Medicines for Seniors Act S.2, Secure America Act
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to reimbursement for biologics/biosimilars Issues related to PBM reform Issues related to bone disease awareness and treatment S.3345, PBM Price Transparency and Accountability Act HR 6166, Lowering Drug Costs for American Families Act S 3019 - No Big Blockbuster Bailouts Act S 3349 PBM Disclosure Act HR 4317 PBM Reform Act Issues related to Public law 117-1769 Inflation Reduction Act HR 1672 Maintaining Investments in New Innovation Act (MINI) HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 PL 119-75 Consolidated Appropriations Act of 2026 HR 8143/S 4323 Ensuring Access to Lower-Cost Medicines for Seniors Act S.2, Secure America Act HR 10628/ S 5571 Biosimilars Access and Affordability Act S 5244 Sustain 340B Act HR 9599 Secure 340B Act
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to reimbursement for biologics/biosimilars Issues related to PBM reform Issues related to bone disease awareness and treatment HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S.3345, PBM Price Transparency and Accountability Act HR 6166, Lowering Drug Costs for American Families Act S 3019 - No Big Blockbuster Bailouts Act S 3349 PBM Disclosure Act HR 4317 PBM Reform Act Issues related to Public law 117-1769 Inflation Reduction Act HR 1492 Ensuring Pathways to Innovative Cures Act (EPIC) HR 1672 Maintaining Investments in New Innovation Act (MINI) HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 PL 119-75 Consolidated Appropriations Act of 2026
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to FDA Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Issues related to biosimilars reimbursement Issues related to Supply Chain Issues related to 340B Issues related to pharmacy benefit managers Issues related to biosimilars regulatory standards Issues related to bone disease awareness and treatment Issues related to Public law 117-1769 Inflation Reduction Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S 1954 Biosimilar Red Tape Elimination Act H.R.5526 Biosimilar Red Tape Elimination Act S.3345 PBM Price Transparency and Accountability Act H.R. 6166 Lowering Drug Costs for American Families Act S.3019 No Big Blockbuster Bailouts Act HR 4317 PBM Reform Act S 3510 Biosimilar Inspection Modernization Act PL 119-75 Consolidated Appropriations Act of 2026 HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 S 3788 Clear Labels Act HR 5256 340B Access Act HR 7391 Community Health Center Drug Pricing Protection Act HR 8143/S 4323 Ensuring Access to Lower-Cost Medicines for Seniors Act S.2, Secure America Act (Reconciliation 2.0) S 3014 Ensuring Timely Access to Generics Act of 2025 S 2355 Patients Deserve Price Tags Act HR 8646 Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 HR 8800 National Defense Authorization Act for Fiscal year 2027 HR 9102 BINSA Bill COINS Act, enacted within P.L. 119-60 National Defense Authorization Act for Fiscal Year 2026 S 1414 Expedited Access to Biosimilars Act HR 10628/ S 5571 Biosimilars Access and Affordability Act S 5244 Sustain 340B Act HR 9599 Secure 340B Act HR 5509/ S 2903 Safe Step Act
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to FDA Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Issues related to biosimilars reimbursement Issues related to Supply Chain Issues related to 340B Issues related to pharmacy benefit managers Issues related to biosimilars regulatory standards Issues related to bone disease awareness and treatment Issues related to Public law 117-1769 Inflation Reduction Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S 1954 Biosimilar Red Tape Elimination Act H.R.5526 Biosimilar Red Tape Elimination Act S.3345 PBM Price Transparency and Accountability Act H.R. 6166 Lowering Drug Costs for American Families Act S.3019 No Big Blockbuster Bailouts Act HR 4317 PBM Reform Act S 3510 Biosimilar Inspection Modernization Act PL 119-75 Consolidated Appropriations Act of 2026 HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 S 3788 Clear Labels Act HR 5256 340B Access Act HR 7391 Community Health Center Drug Pricing Protection Act HR 8143/S 4323 Ensuring Access to Lower-Cost Medicines for Seniors Act S.2, Secure America Act (Reconciliation 2.0) S 3014 Ensuring Timely Access to Generics Act of 2025 S 2355 Patients Deserve Price Tags Act HR 8646 Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 HR 8800 National Defense Authorization Act for Fiscal year 2027 HR 9102 BINSA Bill COINS Act, enacted within P.L. 119-60 National Defense Authorization Act for Fiscal Year 2026 S 1414 Expedited Access to Biosimilars Act
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to reimbursement for biologics/biosimilars Issues related to PBM reform Issues related to bone disease awareness and treatment S.3345, PBM Price Transparency and Accountability Act HR 6166, Lowering Drug Costs for American Families Act S 3019 - No Big Blockbuster Bailouts Act S 3349 PBM Disclosure Act HR 4317 PBM Reform Act Issues related to Public law 117-1769 Inflation Reduction Act HR 1672 Maintaining Investments in New Innovation Act (MINI) HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 PL 119-75 Consolidated Appropriations Act of 2026 HR 8143/S 4323 Ensuring Access to Lower-Cost Medicines for Seniors Act S.2, Secure America Act HR 10628/ S 5571 Biosimilars Access and Affordability Act S 5244 Sustain 340B Act HR 9599 Secure 340B Act
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to reimbursement for biologics/biosimilars Issues related to PBM reform Issues related to bone disease awareness and treatment S.3345, PBM Price Transparency and Accountability Act HR 6166, Lowering Drug Costs for American Families Act S 3019 - No Big Blockbuster Bailouts Act S 3349 PBM Disclosure Act HR 4317 PBM Reform Act Issues related to Public law 117-1769 Inflation Reduction Act HR 1672 Maintaining Investments in New Innovation Act (MINI) HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 PL 119-75 Consolidated Appropriations Act of 2026 HR 8143/S 4323 Ensuring Access to Lower-Cost Medicines for Seniors Act S.2, Secure America Act
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to FDA Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Issues related to biosimilars reimbursement Issues related to Supply Chain Issues related to 340B Issues related to pharmacy benefit managers Issues related to biosimilars regulatory standards Issues related to bone disease awareness and treatment Issues related to Public law 117-1769 Inflation Reduction Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S 1954 Biosimilar Red Tape Elimination Act H.R.5526 Biosimilar Red Tape Elimination Act S.3345 PBM Price Transparency and Accountability Act H.R. 6166 Lowering Drug Costs for American Families Act S.3019 No Big Blockbuster Bailouts Act HR 4317 PBM Reform Act S 3510 Biosimilar Inspection Modernization Act PL 119-75 Consolidated Appropriations Act of 2026 HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 S 3788 Clear Labels Act HR 5256 340B Access Act HR 7391 Community Health Center Drug Pricing Protection Act HR 8143/S 4323 Ensuring Access to Lower-Cost Medicines for Seniors Act S.2, Secure America Act (Reconciliation 2.0) S 3014 Ensuring Timely Access to Generics Act of 2025 S 2355 Patients Deserve Price Tags Act HR 8646 Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 HR 8800 National Defense Authorization Act for Fiscal year 2027 HR 9102 BINSA Bill COINS Act, enacted within P.L. 119-60 National Defense Authorization Act for Fiscal Year 2026 S 1414 Expedited Access to Biosimilars Act HR 10628/ S 5571 Biosimilars Access and Affordability Act S 5244 Sustain 340B Act HR 9599 Secure 340B Act HR 5509/ S 2903 Safe Step Act
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to FDA Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Issues related to biosimilars reimbursement Issues related to Supply Chain Issues related to 340B Issues related to pharmacy benefit managers Issues related to biosimilars regulatory standards Issues related to bone disease awareness and treatment Issues related to Public law 117-1769 Inflation Reduction Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S 1954 Biosimilar Red Tape Elimination Act H.R.5526 Biosimilar Red Tape Elimination Act S.3345 PBM Price Transparency and Accountability Act H.R. 6166 Lowering Drug Costs for American Families Act S.3019 No Big Blockbuster Bailouts Act HR 4317 PBM Reform Act S 3510 Biosimilar Inspection Modernization Act PL 119-75 Consolidated Appropriations Act of 2026 HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 S 3788 Clear Labels Act HR 5256 340B Access Act HR 7391 Community Health Center Drug Pricing Protection Act HR 8143/S 4323 Ensuring Access to Lower-Cost Medicines for Seniors Act S.2, Secure America Act (Reconciliation 2.0) S 3014 Ensuring Timely Access to Generics Act of 2025 S 2355 Patients Deserve Price Tags Act HR 8646 Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 HR 8800 National Defense Authorization Act for Fiscal year 2027 HR 9102 BINSA Bill COINS Act, enacted within P.L. 119-60 National Defense Authorization Act for Fiscal Year 2026 S 1414 Expedited Access to Biosimilars Act
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to FDA Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Issues related to biosimilars reimbursement Issues related to Supply Chain Issues related to 340B Issues related to pharmacy benefit managers Issues related to biosimilars regulatory standards Issues related to bone disease awareness and treatment Issues related to Public law 117-1769 Inflation Reduction Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S 1954 Biosimilar Red Tape Elimination Act H.R.5526 Biosimilar Red Tape Elimination Act S.3345 PBM Price Transparency and Accountability Act H.R. 6166 Lowering Drug Costs for American Families Act S.3019 No Big Blockbuster Bailouts Act HR 4317 PBM Reform Act S 3510 Biosimilar Inspection Modernization Act PL 119-75 Consolidated Appropriations Act of 2026 HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 S 3788 Clear Labels Act HR 5256 340B Access Act HR 7391 Community Health Center Drug Pricing Protection Act HR 8143/S 4323 Ensuring Access to Lower-Cost Medicines for Seniors Act S.2, Secure America Act (Reconciliation 2.0) S 3014 Ensuring Timely Access to Generics Act of 2025 S 2355 Patients Deserve Price Tags Act HR 8646 Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 HR 8800 National Defense Authorization Act for Fiscal year 2027 HR 9102 BINSA Bill COINS Act, enacted within P.L. 119-60 National Defense Authorization Act for Fiscal Year 2026 S 1414 Expedited Access to Biosimilars Act HR 10628/ S 5571 Biosimilars Access and Affordability Act S 5244 Sustain 340B Act HR 9599 Secure 340B Act HR 5509/ S 2903 Safe Step Act
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to FDA Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Issues related to biosimilars reimbursement Issues related to Supply Chain Issues related to 340B Issues related to pharmacy benefit managers Issues related to biosimilars regulatory standards Issues related to bone disease awareness and treatment Issues related to Public law 117-1769 Inflation Reduction Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S 1954 Biosimilar Red Tape Elimination Act H.R.5526 Biosimilar Red Tape Elimination Act S.3345 PBM Price Transparency and Accountability Act H.R. 6166 Lowering Drug Costs for American Families Act S.3019 No Big Blockbuster Bailouts Act HR 4317 PBM Reform Act S 3510 Biosimilar Inspection Modernization Act PL 119-75 Consolidated Appropriations Act of 2026 HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 S 3788 Clear Labels Act HR 5256 340B Access Act HR 7391 Community Health Center Drug Pricing Protection Act HR 8143/S 4323 Ensuring Access to Lower-Cost Medicines for Seniors Act S.2, Secure America Act (Reconciliation 2.0) S 3014 Ensuring Timely Access to Generics Act of 2025 S 2355 Patients Deserve Price Tags Act HR 8646 Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 HR 8800 National Defense Authorization Act for Fiscal year 2027 HR 9102 BINSA Bill COINS Act, enacted within P.L. 119-60 National Defense Authorization Act for Fiscal Year 2026 S 1414 Expedited Access to Biosimilars Act
Rebuilding the United States-Flag International Fleet Act
Client: AMGEN INC · Firm: AMGEN, INC.
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to FDA Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Issues related to biosimilars reimbursement Issues related to Supply Chain Issues related to 340B Issues related to pharmacy benefit managers Issues related to biosimilars regulatory standards Issues related to bone disease awareness and treatment Issues related to Public law 117-1769 Inflation Reduction Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S 1954 Biosimilar Red Tape Elimination Act H.R.5526 Biosimilar Red Tape Elimination Act S.3345 PBM Price Transparency and Accountability Act H.R. 6166 Lowering Drug Costs for American Families Act S.3019 No Big Blockbuster Bailouts Act HR 4317 PBM Reform Act S 3510 Biosimilar Inspection Modernization Act PL 119-75 Consolidated Appropriations Act of 2026 HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 S 3788 Clear Labels Act HR 5256 340B Access Act HR 7391 Community Health Center Drug Pricing Protection Act HR 8143/S 4323 Ensuring Access to Lower-Cost Medicines for Seniors Act S.2, Secure America Act (Reconciliation 2.0) S 3014 Ensuring Timely Access to Generics Act of 2025 S 2355 Patients Deserve Price Tags Act HR 8646 Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 HR 8800 National Defense Authorization Act for Fiscal year 2027 HR 9102 BINSA Bill COINS Act, enacted within P.L. 119-60 National Defense Authorization Act for Fiscal Year 2026 S 1414 Expedited Access to Biosimilars Act
Rebuilding the United States-Flag International Fleet Act
Client: AMGEN INC · Firm: AMGEN, INC.
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to FDA Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Issues related to biosimilars reimbursement Issues related to Supply Chain Issues related to 340B Issues related to pharmacy benefit managers Issues related to biosimilars regulatory standards Issues related to bone disease awareness and treatment Issues related to Public law 117-1769 Inflation Reduction Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S 1954 Biosimilar Red Tape Elimination Act H.R.5526 Biosimilar Red Tape Elimination Act S.3345 PBM Price Transparency and Accountability Act H.R. 6166 Lowering Drug Costs for American Families Act S.3019 No Big Blockbuster Bailouts Act HR 4317 PBM Reform Act S 3510 Biosimilar Inspection Modernization Act PL 119-75 Consolidated Appropriations Act of 2026 HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 S 3788 Clear Labels Act HR 5256 340B Access Act HR 7391 Community Health Center Drug Pricing Protection Act HR 8143/S 4323 Ensuring Access to Lower-Cost Medicines for Seniors Act S.2, Secure America Act (Reconciliation 2.0) S 3014 Ensuring Timely Access to Generics Act of 2025 S 2355 Patients Deserve Price Tags Act HR 8646 Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 HR 8800 National Defense Authorization Act for Fiscal year 2027 HR 9102 BINSA Bill COINS Act, enacted within P.L. 119-60 National Defense Authorization Act for Fiscal Year 2026 S 1414 Expedited Access to Biosimilars Act HR 10628/ S 5571 Biosimilars Access and Affordability Act S 5244 Sustain 340B Act HR 9599 Secure 340B Act HR 5509/ S 2903 Safe Step Act
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to FDA Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Issues related to biosimilars reimbursement Issues related to Supply Chain Issues related to 340B Issues related to pharmacy benefit managers Issues related to biosimilars regulatory standards Issues related to bone disease awareness and treatment Issues related to Public law 117-1769 Inflation Reduction Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S 1954 Biosimilar Red Tape Elimination Act H.R.5526 Biosimilar Red Tape Elimination Act S.3345 PBM Price Transparency and Accountability Act H.R. 6166 Lowering Drug Costs for American Families Act S.3019 No Big Blockbuster Bailouts Act HR 4317 PBM Reform Act S 3510 Biosimilar Inspection Modernization Act PL 119-75 Consolidated Appropriations Act of 2026 HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 S 3788 Clear Labels Act HR 5256 340B Access Act HR 7391 Community Health Center Drug Pricing Protection Act HR 8143/S 4323 Ensuring Access to Lower-Cost Medicines for Seniors Act S.2, Secure America Act (Reconciliation 2.0) S 3014 Ensuring Timely Access to Generics Act of 2025 S 2355 Patients Deserve Price Tags Act HR 8646 Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 HR 8800 National Defense Authorization Act for Fiscal year 2027 HR 9102 BINSA Bill COINS Act, enacted within P.L. 119-60 National Defense Authorization Act for Fiscal Year 2026 S 1414 Expedited Access to Biosimilars Act HR 10628/ S 5571 Biosimilars Access and Affordability Act S 5244 Sustain 340B Act HR 9599 Secure 340B Act HR 5509/ S 2903 Safe Step Act
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to reimbursement for biologics/biosimilars Issues related to PBM reform Issues related to bone disease awareness and treatment S.3345, PBM Price Transparency and Accountability Act HR 6166, Lowering Drug Costs for American Families Act S 3019 - No Big Blockbuster Bailouts Act S 3349 PBM Disclosure Act HR 4317 PBM Reform Act Issues related to Public law 117-1769 Inflation Reduction Act HR 1672 Maintaining Investments in New Innovation Act (MINI) HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 PL 119-75 Consolidated Appropriations Act of 2026 HR 8143/S 4323 Ensuring Access to Lower-Cost Medicines for Seniors Act S.2, Secure America Act HR 10628/ S 5571 Biosimilars Access and Affordability Act S 5244 Sustain 340B Act HR 9599 Secure 340B Act
Issues related to corporate and international tax Public Law 115-97, Tax Cuts and Jobs Act Public Law 119-21, One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) Issues related to Puerto Rico Issues related to OECD negotiations on the taxation of global income
Federal Trade Commission related issues Issues related to the Patent Act, no specific bill Issues related to March-In/Bayh Dole, WTO/TRIPS Issues related to patent thickets Issues related to obviousness/ double patenting Issues related to FDA/PTO coordination Issues related to skinny labeling S.1041 A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes S.1040 -A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes S 708/ HR 1574 -- Realizing Engineering, Science and Technology Opportunities by Restoring Exclusive Patent Rights Act of 2025 (RESTORE) S.1553/HR3160-- Promoting and Respecting Economically Viable American Innovation Act (PREVAIL) S. 1546/ HR 3152-- Patent Eligibility Restoration Act of 2025 (PERA) S 2276 / HR 3269 Eliminating Thickets to Increase Competition Act (ETHIC Act) S. 43/HR 6485 Skinny Labels Big Savings Act S.2658 Medication Affordability and Patent Integrity Act S. 3452/HR 6624 Biological Intellectual Property Protection Act of 2025
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to reimbursement for biologics/biosimilars Issues related to PBM reform Issues related to bone disease awareness and treatment S.3345, PBM Price Transparency and Accountability Act HR 6166, Lowering Drug Costs for American Families Act S 3019 - No Big Blockbuster Bailouts Act S 3349 PBM Disclosure Act HR 4317 PBM Reform Act Issues related to Public law 117-1769 Inflation Reduction Act HR 1672 Maintaining Investments in New Innovation Act (MINI) HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 PL 119-75 Consolidated Appropriations Act of 2026 HR 8143/S 4323 Ensuring Access to Lower-Cost Medicines for Seniors Act S.2, Secure America Act HR 10628/ S 5571 Biosimilars Access and Affordability Act S 5244 Sustain 340B Act HR 9599 Secure 340B Act
Issues related to tariffs Issues related to trade agreements S. 3452/HR 6624 Biological Intellectual Property Protection Act of 2025
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Treasury, Dept of
AMGEN INC via AMGEN, INC.
2026 · second_quarter · Q2
Issues related to tariffs Issues related to trade agreements S. 3452/HR 6624 Biological Intellectual Property Protection Act of 2025
Issues related to corporate and international tax Public Law 115-97, Tax Cuts and Jobs Act Public Law 119-21, One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) Issues related to Puerto Rico Issues related to OECD negotiations on the taxation of global income
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to FDA Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Issues related to biosimilars reimbursement Issues related to Supply Chain Issues related to 340B Issues related to pharmacy benefit managers Issues related to biosimilars regulatory standards Issues related to bone disease awareness and treatment Issues related to Public law 117-1769 Inflation Reduction Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S 1954 Biosimilar Red Tape Elimination Act H.R.5526 Biosimilar Red Tape Elimination Act S.3345 PBM Price Transparency and Accountability Act H.R. 6166 Lowering Drug Costs for American Families Act S.3019 No Big Blockbuster Bailouts Act HR 4317 PBM Reform Act S 3510 Biosimilar Inspection Modernization Act PL 119-75 Consolidated Appropriations Act of 2026 HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 S 3788 Clear Labels Act HR 5256 340B Access Act HR 7391 Community Health Center Drug Pricing Protection Act HR 8143/S 4323 Ensuring Access to Lower-Cost Medicines for Seniors Act S.2, Secure America Act (Reconciliation 2.0) S 3014 Ensuring Timely Access to Generics Act of 2025 S 2355 Patients Deserve Price Tags Act HR 8646 Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 HR 8800 National Defense Authorization Act for Fiscal year 2027 HR 9102 BINSA Bill COINS Act, enacted within P.L. 119-60 National Defense Authorization Act for Fiscal Year 2026 S 1414 Expedited Access to Biosimilars Act
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to reimbursement for biologics/biosimilars Issues related to PBM reform Issues related to bone disease awareness and treatment S.3345, PBM Price Transparency and Accountability Act HR 6166, Lowering Drug Costs for American Families Act S 3019 - No Big Blockbuster Bailouts Act S 3349 PBM Disclosure Act HR 4317 PBM Reform Act Issues related to Public law 117-1769 Inflation Reduction Act HR 1672 Maintaining Investments in New Innovation Act (MINI) HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 PL 119-75 Consolidated Appropriations Act of 2026 HR 8143/S 4323 Ensuring Access to Lower-Cost Medicines for Seniors Act S.2, Secure America Act
Federal Trade Commission related issues Issues related to the Patent Act, no specific bill Issues related to March-In/Bayh Dole, WTO/TRIPS Issues related to patent thickets Issues related to obviousness/ double patenting Issues related to FDA/PTO coordination Issues related to skinny labeling S.1041 A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes S.1040 -A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes S 708/ HR 1574 -- Realizing Engineering, Science and Technology Opportunities by Restoring Exclusive Patent Rights Act of 2025 (RESTORE) S.1553/HR3160-- Promoting and Respecting Economically Viable American Innovation Act (PREVAIL) S. 1546/ HR 3152-- Patent Eligibility Restoration Act of 2025 (PERA) S 2276 / HR 3269 Eliminating Thickets to Increase Competition Act (ETHIC Act) S. 43/HR 6485 Skinny Labels Big Savings Act S.2658 Medication Affordability and Patent Integrity Act S. 3452/HR 6624 Biological Intellectual Property Protection Act of 2025
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Treasury, Dept of
AMGEN INC via AMGEN, INC.
2026 · first_quarter · Q1
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to FDA Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Issues related to biosimilars reimbursement Issues related to Supply Chain Issues related to 340B Issues related to pharmacy benefit managers Issues related to biosimilars regulatory standards Issues related to bone disease awareness and treatment Issues related to Public law 117-1769 Inflation Reduction Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S 1954 Biosimilar Red Tape Elimination Act S.3345 PBM Price Transparency and Accountability Act H.R. 6166 Lowering Drug Costs for American Families Act S.3019 No Big Blockbuster Bailouts Act HR 4317 PBM Reform Act S 3510 Biosimilar Inspection Modernization Act PL 119-75 Consolidated Appropriations Act of 2026 HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 S 3788 Clear Labels Act HR 5256 340B Access Act H.R.5526 Biosimilar Red Tape Elimination Act HR 7391 Community Health Center Drug Pricing Protection Act
Issues related to tariffs Issues related to trade agreements S. 3452/HR 6624 Biological Intellectual Property Protection Act of 2025
Issues related to corporate and international tax Public Law 115-97, Tax Cuts and Jobs Act Public Law 119-21, One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) Issues related to Puerto Rico Issues related to OECD negotiations on the taxation of global income
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to reimbursement for biologics/biosimilars Issues related to PBM reform Issues related to bone disease awareness and treatment HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S.3345, PBM Price Transparency and Accountability Act HR 6166, Lowering Drug Costs for American Families Act S 3019 - No Big Blockbuster Bailouts Act S 3349 PBM Disclosure Act HR 4317 PBM Reform Act Issues related to Public law 117-1769 Inflation Reduction Act HR 1492 Ensuring Pathways to Innovative Cures Act (EPIC) HR 1672 Maintaining Investments in New Innovation Act (MINI) HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 PL 119-75 Consolidated Appropriations Act of 2026
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Treasury, Dept of
AMGEN INC via AMGEN, INC.
2025 · fourth_quarter · Q4
Issues related to drug pricing Issues related to Public law 117-1769 Inflation Reduction Act Issues related to cardiovascular disease awareness and treatment Issues related to reimbursement for biologics/biosimilars Issues related to PBM reform Issues related to bone disease awareness and treatment HR 946 Optimizing Research Progress Hope and New Cures Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) H.R.1968 - Full-Year Continuing Appropriations and Extensions Act, 2025 S.3345, PBM Price Transparency and Accountability Act H.R. 6166, Lowering Drug Costs for American Families Act S.3019 - No Big Blockbuster Bailouts Act H.Res. 928 - Affirming support for most-favored-Nation drug pricing for United States patients S 3349 PBM Disclosure Act HR 4317 PBM Reform Act
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to FDA Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Issues related to biosimilars reimbursement Issues related to Supply Chain Issues related to 340B Issues related to pharmacy benefit managers Issues related to biosimilars regulatory standards Issues related to bone disease awareness and treatment Issues related to Public law 117-1769 Inflation Reduction Act Issues pertaining to the implementation of PL 97-414 "Orphan Drug Act," all provisions. HR 946 Optimizing Research Progress Hope and New Cures Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S 1954 Biosimilar Red Tape Elimination Act HR 5526 Biosimilar Red Tape Elimination Act HR 2214 DRUG Act H.R.1968 - Full-Year Continuing Appropriations and Extensions Act, 2025 HR 5509 Safe Step act HR 5256 340B Access Act HR 4581 340B Patients Act S2296 NDAA FY2026 National Defense Authorization Act, issued related to Biosecure Act H.R. 6703 Lower Health Care Premiums for All Americans Act S.3345 PBM Price Transparency and Accountability Act H.R. 6166 Lowering Drug Costs for American Families Act S.3019 No Big Blockbuster Bailouts Act H.Res. 928 Affirming support for most-favored-Nation drug pricing for United States patients S 3349 PBM Disclosure Act HR 4317 PBM Reform Act S 3510 Biosimilar Inspection Modernization Act
Issues related to corporate and international tax, including regarding Public Law 115-97, Tax Cuts and Jobs Act Issues related to Puerto Rico Issues related to OECD negotiations on the taxation of global income Public Law 119-21, One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) Issues related to patents and taxes
Issues related to tariffs.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Treasury, Dept of
AMGEN INC via AMGEN, INC.
2025 · second_quarter · 2A
Issues related to drug pricing Changes to Public law 117-1769 Inflation Reduction Act Awareness of implications to patients and research and development of Public law 117-1769 Inflation Reduction Act Issues related to cardiovascular disease awareness and treatment Issues related to FDA Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Issues related to biosimilars reimbursement Issues related to Supply Chain Issues related to 340B Issues related to pharmacy benefit managers Issues pertaining to the implementation of PL 97-414 "Orphan Drug Act," all provisions. Issues related to biosimilars regulatory standards Issues related to bone disease awareness and treatment Issues related to pediatric priority review voucher reauthorization HR 946 Optimizing Research Progress Hope and New Cures Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 2214 DRUG Act H.R.1968 - Full-Year Continuing Appropriations and Extensions Act, 2025 HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S 1954 Biosimilar Red Tape Elimination Act
Issues related to drug pricing Changes to Public law 117-1769 Inflation Reduction Act Awareness of implications to patients and research and development of Public law 117-1769 Inflation Reduction Act Issues related to cardiovascular disease awareness and treatment Issues related to reimbursement for biologics/biosimilars Issues related to PBM reform Issues related to bone disease awareness and treatment HR 946 Optimizing Research Progress Hope and New Cures Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act H.R.1968 - Full-Year Continuing Appropriations and Extensions Act, 2025 HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14)
Issues related to corporate and international tax, including regarding Public Law 115-97, Tax Cuts and Jobs Act Issues related to Puerto Rico Issues related to OECD negotiations on the taxation of global income HR 1328 Supply Chain Security and Growth Act of 2025 HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14)
Issues related to tariffs.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Treasury, Dept of
AMGEN INC via AMGEN, INC.
2025 · third_quarter · Q3
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to FDA Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Issues related to biosimilars reimbursement Issues related to Supply Chain Issues related to 340B Issues related to pharmacy benefit managers Issues related to biosimilars regulatory standards Issues related to bone disease awareness and treatment Issues related to Public law 117-1769 Inflation Reduction Act Issues pertaining to the implementation of PL 97-414 "Orphan Drug Act," all provisions. HR 946 Optimizing Research Progress Hope and New Cures Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S 1954 Biosimilar Red Tape Elimination Act HR 5526 Biosimilar Red Tape Elimination Act HR 2214 DRUG Act H.R.1968 - Full-Year Continuing Appropriations and Extensions Act, 2025 HR 5509 Safe Step act HR 5256 340B Access Act HR 4581 340B Patients Act S2296 NDAA FY2026 National Defense Authorization Act, issued related to Biosecure Act
AMGEN INC via AMGEN, INC.
2025 · second_quarter · Q2
Issues related to drug pricing Changes to Public law 117-1769 Inflation Reduction Act Awareness of implications to patients and research and development of Public law 117-1769 Inflation Reduction Act Issues related to cardiovascular disease awareness and treatment Issues related to FDA Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Issues related to biosimilars reimbursement Issues related to Supply Chain Issues related to 340B Issues related to pharmacy benefit managers Issues pertaining to the implementation of PL 97-414 "Orphan Drug Act," all provisions. Issues related to biosimilars regulatory standards Issues related to bone disease awareness and treatment Issues related to pediatric priority review voucher reauthorization HR 946 Optimizing Research Progress Hope and New Cures Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 2214 DRUG Act H.R.1968 - Full-Year Continuing Appropriations and Extensions Act, 2025 HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S 1954 Biosimilar Red Tape Elimination Act
AMGEN INC via AMGEN, INC.
2025 · first_quarter · Q1
Issues related to drug pricing reform -Changes to Public law 117-1769 Inflation Reduction Act -Awareness of implications to patients and research and development of Public law 117-1769 Inflation Reduction Act Issues related to cardiovascular disease awareness and treatment Issues related to FDA Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Issues related to biosimilars reimbursement Issues related to Supply Chain Issues related to 340B Issues related to pharmacy benefit managers Issues pertaining to the implementation of PL 97-414 "Orphan Drug Act," all provisions. Issues related to prohibiting the export of biotechnology to certain foreign entities (BIOCOMPETE) Issues related to direct-to-consumer advertising Issues related to obesity disease awareness and treatment Issues related to biosimilars regulatory standards Issues related to bone disease awareness and treatment Issues related to pediatric priority review voucher reauthorization HR 946 Optimizing Research Progress Hope and New Cures Act HR 1492 Insuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 2214 DRUG Act H.R.1968 - Full-Year Continuing Appropriations and Extensions Act, 2025 S.Con.Res.7 - An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034. H.Con.Res.14 - Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034.
AMGEN INC via AMGEN, INC.
2024 · fourth_quarter · Q4
Issues related to drug pricing reform Changes to Public law 117-1769 Inflation Reduction Act Awareness of implications to patients and research and development of Public law 117-1769 Inflation Reduction Act S. 113 Prescription Pricing for the People Act of 2023 S.127 Pharmacy Benefit Manager Transparency Act HR 830/ S 1375 HELP Copays Act HR 485 Protecting Health Care for All Patients Act HR 5378 Lower Costs, More Transparency Act R 2534 PROTECT 340B Act of 2023 HR 3561 the PATIENT Act S. 1542 DRUG Act S. 1967 PBM Act HR 3503 The NIH Clinical Trials Diversity Act Issues related to cardiovascular disease awareness and treatment Issues related to Federal Trade Commission FDA issues Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Biosimilars reimbursement issues, no specific bill Supply Chain Issues, no specific bill Issues related to 340B Issues related to pharmacy benefit managers Proposed rule: Medicaid Program; Misclassification of Drugs, Program Administration and Program Integrity Updates Under the Medicaid Drug Rebate Program HR 4818/ S. 2407 Treat and Reduce Obesity Act S. 2305 Biosimilar Red Tape Elimination Act S. 2129 Ensuring Access to Lower-Cost Medicines for Seniors Act Issues related to PAHPA reauthorization Modernizing and Ensuring PBM Accountability Act (Finance Committee) S. 652/ HR2630 SAFE Step Act S 2474/ HR 5376 Share the Savings with Seniors Act S 2456 Protecting Seniors from High Drug Costs Act HR4881 To amend title XVIII of the Social Security Act to limit cost sharing for drugs under the Medicare program HR 3281 Protecting Patients Against PBM Abuses Act HR 4822 Health Care Price Transparency Act of 2023 S 1339 Pharmacy Benefit Manager Reform Act HR 2679 Pharmacy Benefits Manager Accountability Act HR 4507 Transparency in Coverage Act of 2023 HR 1352 Increasing Access to Biosimilars Act of 2023 HR 2880 Protecting Patients Against PBM Abuses Act Issues pertaining to the implementation of PL 97-414 "Orphan Drug Act," all provisions. HR 5539 Orphan Cures Act HR 5547 Maintaining Investments in New Innovation Act S 3558 BIOSECURE Act HR 7174 Ensuring Pathways to Innovative Cures (EPIC Act) S Res 566 Cholesterol Education Month 2024 HR 7635 340B PATIENTS Act of 2024 H.R. 5391 / S. 2764 The Protecting Patient Access to Cancer and Complex Therapies Act H.R.8574 - 340B Affording Care for Communities and Ensuring a Strong Safety-net Act. HR 5376 Share the Savings With Seniors Act S 3430 Mental Health, Lower Cost Drugs and Extenders Package. BIOCOMPETE (no bill number)- Issues related to prohibiting the export of biotechnology to certain foreign entities HR 8412 Clinical Trial Modernization Act S 5573 Skinny Labels, Big Savings Act HR 10515 American Relief Act
AMGEN INC via AMGEN, INC.
2024 · third_quarter · Q3
Issues related to drug pricing reform Changes to Public law 117-1769 Inflation Reduction Act Awareness of implications to patients and research and development of Public law 117-1769 Inflation Reduction Act S. 113 Prescription Pricing for the People Act of 2023 S.127 Pharmacy Benefit Manager Transparency Act HR 485 Protecting Health Care for All Patients Act HR 5378 Lower Costs, More Transparency Act HR 2534 PROTECT 340B act of 2023 HR 3561 the PATIENT act Issues related to cardiovascular disease awareness and treatment Issues related to ESRD Issues related to asthma and self-administered drug list Issues related to reimbursement for biologics/biosimilars Proposed rule: Medicaid Program; Misclassification of Drugs, Program Administration and Program Integrity Updates Under the Medicaid Drug Rebate Program HR 4818/ S2407 Treat and Reduce Obesity Act S. 2129 Ensuring Access to Lower-Cost Medicines for Seniors Act Issues related to PAHPA reauthorization Modernizing and Ensuring PBM Accountability Act (Finance Committee) S. 1542/HR 6283 DRUG Act S652 SAFE Step Act HR 3281 Protecting Patients Against PBM Abuses Act HR 4822 Health Care Price Transparency Act of 2023 S 1339 Pharmacy Benefit Manager Reform Act HR 2679 Pharmacy Benefits Manager Accountability Act HR 4507 Transparency in Coverage Act of 2023 S 2474/HR 5376 Share the Savings with Seniors Act S 2456 Protecting Seniors from High Drug Costs Act HR4881 To amend title XVIII of the Social Security Act to limit cost sharing for drugs under the Medicare program HR 1352 Increasing Access to Biosimilars Act of 2023 HR 2880 Protecting Patients Against PBM Abuses Act HR 5547 Maintaining Investments in New Innovation Act HR 7174 Ensuring Pathways to Innovative Cures (EPIC Act) HR 7635 340B PATIENTS Act of 2024 H.R. 5391 / S. 2764 The Protecting Patient Access to Cancer and Complex Therapies Act H.R.8574 - 340B Affording Care for Communities and Ensuring a Strong Safety-net Act. HR 5376 Share the Savings With Seniors Act. S 3430 Mental Health, Lower Cost Drugs and Extenders Package HR 5539 Orphan Cures Act
Issues related to drug pricing Issues related to Public law 117-1769 Inflation Reduction Act Issues related to cardiovascular disease awareness and treatment Issues related to reimbursement for biologics/biosimilars Issues related to PBM reform Issues related to bone disease awareness and treatment HR 946 Optimizing Research Progress Hope and New Cures Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) H.R.1968 - Full-Year Continuing Appropriations and Extensions Act, 2025
Issues related to corporate and international tax, including regarding Public Law 115-97, Tax Cuts and Jobs Act Issues related to Puerto Rico Issues related to OECD negotiations on the taxation of global income HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14)
Issues related to tariffs.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Treasury, Dept of
Issues related to drug pricing Changes to Public law 117-1769 Inflation Reduction Act Awareness of implications to patients and research and development of Public law 117-1769 Inflation Reduction Act Issues related to cardiovascular disease awareness and treatment Issues related to reimbursement for biologics/biosimilars Issues related to PBM reform Issues related to bone disease awareness and treatment HR 946 Optimizing Research Progress Hope and New Cures Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act H.R.1968 - Full-Year Continuing Appropriations and Extensions Act, 2025 HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14)
Issues related to corporate and international tax, including regarding Public Law 115-97, Tax Cuts and Jobs Act Issues related to Puerto Rico Issues related to OECD negotiations on the taxation of global income HR 1328 Supply Chain Security and Growth Act of 2025 HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14)
Issues related to tariffs.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to drug pricing reform Changes to Public law 117-1769 Inflation Reduction Act Awareness of implications to patients and research and development of Public law 117-1769 Inflation Reduction Act Issues related to cardiovascular disease awareness and treatment Issues related to reimbursement for biologics/biosimilars Issues related to PBM reform Issues related to obesity disease awareness and treatment Issues related to bone disease awareness and treatment HR 946 Optimizing Research Progress Hope and New Cures Act HR 1492 Insuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act H.R.1968 - Full-Year Continuing Appropriations and Extensions Act, 2025 S.Con.Res.7 - An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034. H.Con.Res.14 - Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to drug pricing reform Changes to Public law 117-1769 Inflation Reduction Act Awareness of implications to patients and research and development of Public law 117-1769 Inflation Reduction Act S. 113 Prescription Pricing for the People Act of 2023 S.127 Pharmacy Benefit Manager Transparency Act HR 485 Protecting Health Care for All Patients Act HR 5378 Lower Costs, More Transparency Act HR 2534 PROTECT 340B act of 2023 HR 3561 the PATIENT act Issues related to cardiovascular disease awareness and treatment Issues related to ESRD Issues related to asthma and self-administered drug list Issues related to reimbursement for biologics/biosimilars Proposed rule: Medicaid Program; Misclassification of Drugs, Program Administration and Program Integrity Updates Under the Medicaid Drug Rebate Program HR 4818/ S2407 Treat and Reduce Obesity Act S. 2129 Ensuring Access to Lower-Cost Medicines for Seniors Act Issues related to PAHPA reauthorization Modernizing and Ensuring PBM Accountability Act (Finance Committee) S. 1542/HR 6283 DRUG Act S652 SAFE Step Act HR 3281 Protecting Patients Against PBM Abuses Act HR 4822 Health Care Price Transparency Act of 2023 S 1339 Pharmacy Benefit Manager Reform Act HR 2679 Pharmacy Benefits Manager Accountability Act HR 4507 Transparency in Coverage Act of 2023 S 2474/HR 5376 Share the Savings with Seniors Act S 2456 Protecting Seniors from High Drug Costs Act HR4881 To amend title XVIII of the Social Security Act to limit cost sharing for drugs under the Medicare program HR 1352 Increasing Access to Biosimilars Act of 2023 HR 2880 Protecting Patients Against PBM Abuses Act HR 5547 Maintaining Investments in New Innovation Act HR 7174 Ensuring Pathways to Innovative Cures (EPIC Act) HR 7635 340B PATIENTS Act of 2024 H.R. 5391 / S. 2764 The Protecting Patient Access to Cancer and Complex Therapies Act H.R.8574 - 340B Affording Care for Communities and Ensuring a Strong Safety-net Act. HR 5376 Share the Savings With Seniors Act. S 3430 Mental Health, Lower Cost Drugs and Extenders Package HR 5539 Orphan Cures Act HR 10515 American Relief Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to drug pricing reform Changes to Public law 117-1769 Inflation Reduction Act Awareness of implications to patients and research and development of Public law 117-1769 Inflation Reduction Act S. 113 Prescription Pricing for the People Act of 2023 S.127 Pharmacy Benefit Manager Transparency Act HR 830/ S 1375 HELP Copays Act HR 485 Protecting Health Care for All Patients Act HR 5378 Lower Costs, More Transparency Act R 2534 PROTECT 340B Act of 2023 HR 3561 the PATIENT Act S. 1542 DRUG Act S. 1967 PBM Act HR 3503 The NIH Clinical Trials Diversity Act Issues related to cardiovascular disease awareness and treatment Issues related to Federal Trade Commission FDA issues Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Biosimilars reimbursement issues, no specific bill Supply Chain Issues, no specific bill Issues related to 340B Issues related to pharmacy benefit managers Proposed rule: Medicaid Program; Misclassification of Drugs, Program Administration and Program Integrity Updates Under the Medicaid Drug Rebate Program HR 4818/ S. 2407 Treat and Reduce Obesity Act S. 2305 Biosimilar Red Tape Elimination Act S. 2129 Ensuring Access to Lower-Cost Medicines for Seniors Act Issues related to PAHPA reauthorization Modernizing and Ensuring PBM Accountability Act (Finance Committee) S. 652/ HR2630 SAFE Step Act S 2474/ HR 5376 Share the Savings with Seniors Act S 2456 Protecting Seniors from High Drug Costs Act HR4881 To amend title XVIII of the Social Security Act to limit cost sharing for drugs under the Medicare program HR 3281 Protecting Patients Against PBM Abuses Act HR 4822 Health Care Price Transparency Act of 2023 S 1339 Pharmacy Benefit Manager Reform Act HR 2679 Pharmacy Benefits Manager Accountability Act HR 4507 Transparency in Coverage Act of 2023 HR 1352 Increasing Access to Biosimilars Act of 2023 HR 2880 Protecting Patients Against PBM Abuses Act Issues pertaining to the implementation of PL 97-414 "Orphan Drug Act," all provisions. HR 5539 Orphan Cures Act HR 5547 Maintaining Investments in New Innovation Act S 3558 BIOSECURE Act HR 7174 Ensuring Pathways to Innovative Cures (EPIC Act) S Res 566 Cholesterol Education Month 2024 HR 7635 340B PATIENTS Act of 2024 H.R. 5391 / S. 2764 The Protecting Patient Access to Cancer and Complex Therapies Act H.R.8574 - 340B Affording Care for Communities and Ensuring a Strong Safety-net Act. HR 5376 Share the Savings With Seniors Act S 3430 Mental Health, Lower Cost Drugs and Extenders Package. BIOCOMPETE (no bill number)- Issues related to prohibiting the export of biotechnology to certain foreign entities HR 8412 Clinical Trial Modernization Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE